Podcasts about tirzepatide

Semaglutide, Tirzepatide, and Retatrutide are often grouped together as GLP-1 medications, but they are not simply three versions of the same drug. In this episode, I compare the biology, research, and real-world implications behind each compound, looking beyond the number on the scale to ask a more useful question: what type of weight is being lost?I break down the progression from single agonist to dual agonist to triple agonist, including how GLP-1, GIP, and glucagon signaling may influence appetite, glucose regulation, energy expenditure, and fat loss. I also examine what the available body composition research shows about lean mass, visceral fat, skeletal muscle, and the risk of becoming lighter without becoming healthier or stronger.Topics discussed: - What actually separates the major GLP-1 medications- The scale - The body composition - Current evidence about retatrutide- Muscle prevention - Framework for evaluating weight loss outcomes---------- ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠My Live Program for Coaches: The Functional Nutrition and Metabolism Specialization ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.metabolismschool.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠---------- [Free] Metabolism School 101: The Video Series⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠http://www.metabolismschool.com/metabolism-101⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠----------Subscribe to My Youtube Channel: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://youtube.com/@sammillerscience?si=s1jcR6Im4GDHbw_1⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠----------⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Grab a Copy of My New Book - Metabolism Made Simple⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠---------- Stay Connected: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram: @sammillerscience⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Youtube: SamMillerScience⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Facebook: The Nutrition Coaching Collaborative Community⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TikTok: @sammillerscience⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠----------“This Podcast is for general informational purposes only and does not constitute the practice of medicine, nursing or other professional health care services, including the giving of medical advice, and no doctor/patient relationship is formed. The use of information on this podcast and the show notes or the reliance on the information provided is to be done at the user's own risk. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment and is for educational purposes only. Always consult your physician before beginning any exercise program and users should not disregard, or delay in obtaining, medical advice for any medical condition they may have and should seek the assistance of their health care professionals for any such conditions. By accessing this Podcast, the listener acknowledges that the entire contents and design of this Podcast, are the property of Oracle Athletic Science LLC, or used by Oracle Athletic Science LLC with permission, and are protected under U.S. and international copyright and trademark laws. Except as otherwise provided herein, users of this Podcast may save and use information contained in the Podcast only for personal or other non-commercial, educational purposes. No other use, including, without limitation, reproduction, retransmission or editing, of this Podcast may be made without the prior written permission of Oracle Athletic Science LLC, which may be requested by contacting the Oracle Athletic Science LLC by email at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠operations⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@sammillerscience.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. By accessing this Podcast, the listener acknowledges that Oracle Athletic Science LLC makes no warranty, guarantee, or representation as to the accuracy or sufficiency of the information featured in this Podcast."

Episode 2853 - Vinnie Tortorich and Anna Vocino discuss food labels, how misconceptions about zero calories can cause big problems, and Tirzepatide. https://vinnietortorich.com/2026/09/zero-calories-big-problems-episode-2853 PLEASE SUPPORT OUR SPONSORS Pure Vitamin Club Pure Coffee Club NSNG® Foods VILLA CAPPELLI EAT HAPPY KITCHEN YOU CAN WATCH THIS EPISODE ON YOUTUBE - @FitnessConfidential Podcast Vinnie's workout videos are available to purchase! Choose from a 2-day, 4-day, or 6-day workout–or buy all three at a discount! TO PURCHASE VINNIE'S WORKOUT VIDEOS, CLICK THIS LINK: https://vinnietortorich.com/workout Zero Calories, Big Problems Anna gives an update on her experience with Xanax for her dental appointment. (9:00) Vinnie is considering opening up the NSNG® VIP group for his upcoming birthday. (15:00) Anna frequents Reddit groups, and she found one about food labels. (17:00) She reads an entry about a woman's misunderstanding about "zero" calories and a candy product. Vinnie breaks down why "zero" calories isn't working. Anna shares an interesting conversation she recently had with a friend who sources ingredients for various food products. (32:00) There are misconceptions about the differences between European foods and American foods. Society and culture have pushed good, natural things out. We had everything, we're getting rid of everything, and we're trying to get back to everything. (39:00) "Organic" is a big lie; certain other certifications can be challenged as well. Tirzepatide for the Heart? Tirzepatide is being approved to reduce cardiovascular risk in adults with T2 Diabetes. (53:00) There is confusion behind its use for the heart. The best treatment for T2 diabetes is cutting sugar and grains and moving your body. (57:45) Anna's next cookbook, Eat Happy Cocktail Hour, is filled with cocktails, mocktails, and appetizers and is available for pre-order right now. If you pre-order, you'll get bonus goodies! You can pre-order from a wide variety of booksellers at https://eathappycocktailhour.com/ Please save your receipt from wherever you pre-order; you'll need it for your bonuses! The physical release date is October 13, 2026 Check out the Aletha Hip HookTM that Vinnie uses to reduce pain and increase mobility: You can purchase your own through Vinnie's website here: https://vinnietortorich.com/hook Anna's products are now linked to PureVitamin Club's website. Look under the "Food and Snacks" section to purchase them there, too. https://purevitaminclub.com/collections/food-and-snacks Vinnie hopes to add other products as well, all of which will be health-related. The NSNG® VIP GROUP IS NOW CLOSED AGAIN AS OF SUNDAY, MARCH 15TH You can book a consultation with Vinnie to get guidance on your goals. https://vinnietortorich.com/phone-consultation-2/ More News Serena has added some of her clothing suggestions and beauty product suggestions to Vinnie's Amazon Recommended Products link. Self Care, Beauty, and Grooming Products that Actually Work! https://www.amazon.com/shop/vinnietortorich/list/3GPVU29UHHPMY?ref_=aipsflist Don't forget to check out Serena Scott Thomas on Days of Our Lives on Peacock. "Dirty Keto" is available on Amazon! You can purchase or rent it here.https://amzn.to/4d9agj1 Please watch, rate, and review it! Eat Happy Italian, Anna's second cookbook, is available! You can go to https://eathappyitalian.com You can order it from Vinnie's Book Club. https://amzn.to/3ucIXm Anna's recipes are in her cookbooks, on her website, and on Substack —they will spice up your day! https://annavocino.substack.com/ PURCHASE DIRTY KETO (2024) The documentary launched in August 2024! Order it TODAY! This is Vinnie's fourth documentary in just over five years. Visit my new Documentaries HQ to find my films everywhere: https://vinnietortorich.com/documentaries Then, please share my fact-based, health-focused documentary series with your friends and family. Additionally, the more views it receives, the better it ranks, so please watch it again with a new friend! REVIEWS: Please submit your REVIEW after you watch my films. Your positive REVIEW does matter! PURCHASE BEYOND IMPOSSIBLE (2022) Visit my new Documentaries HQ to find my films everywhere: https://vinnietortorich.com/documentaries FAT: A DOCUMENTARY 2 (2021) Visit my new Documentaries HQ to find my films everywhere: https://vinnietortorich.com/documentaries FAT: A DOCUMENTARY (2019) Visit my new Documentaries HQ to find my films everywhere: https://vinnietortorich.com/documentaries

Nutrition Nugget! Bite-sized bonus episodes offer tips, tricks and approachable science. This week, Jenn is talking about Retatrutide, the third-generation injectable making waves as the most powerful weight-loss drug studied yet. It targets three hormone pathways at once instead of just one or two, and early trial participants have lost staggering amounts of weight, some over 30 percent of their body weight. But is more always better? Jenn breaks down how this triple mechanism works in the body, what the research shows so far, and why it might finally help the roughly 10 percent of people who never responded to earlier GLP-1s. Still, she has been raising the same concerns since Ozempic first came onto the scene, and this new drug is no exception. Is Retatrutide the breakthrough the weight loss world has been waiting for, or just a stronger version of the same unanswered questions? Tune in to hear Jenn's full take. Like what you're hearing? Be sure to check out the full-length episodes of new releases every Wednesday. Have an idea for a nutrition nugget? Submit it here: https://asaladwithasideoffries.com/index.php/contact/ RESOURCES:Become a Happy Healthy Hub MemberJenn's Free Menu PlanA Salad With a Side of FriesA Salad With A Side Of Fries MerchA Salad With a Side of Fries InstagramOzempicAmerican Diabetes Association Retatrutide—A Game Changer in Obesity Pharmacotherapy - PMCGlucagon | HormonesInternational Journal of Molecular SciencesHyperglycemia vs. Hypoglycemia: Differences in Causes and Symptoms - GoodRxGlucagon Control on Food Intake and Energy Balance - PMCLilly Phase 3 StudyComparative efficacy and safety of GLP-1 receptor agonists for weight reduction: A model-based meta-analysis of placebo-controlled trials - ScienceDirectLilly - RetatrutideWhat Is Osteoarthritis? Causes, Symptoms, and Treatments - GoodRxPotential Retatrutide Benefits You Should Know About - GoodRxClinical TrialsStudy Details | NCT07165028 | A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) | ClinicalTrials.govClinical TrialsStudy Details | NCT06383390 | The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)ClinicalTrials.govClinical TrialsNCT07035093 | A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain | ClinicalTrials.gov11 GLP-1 Side Effects You Should Know About - GoodRxTriple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial | New England Journal of Medicine Counterfeit DrugsPeptides for Weight Loss: What They Are and How They Work - GoodRxJenn Trepeck, Nutrition Nugget, Salad With A Side Of Fries, Health Tips, Wellness Tips, Retatrutide, Glp 1, Gip, Glucagon, Weight Loss, Ozempic, Wegovy, Mounjaro, Zepbound, Tirzepatide, Semaglutide, Insulin Sensitivity, Gastric Emptying, Appetite Suppression, Blood Sugar Control, A1c, Glycated Hemoglobin, Liver Steatosis, Fatty Liver Disease, Diabetic Kidney Disease, Type 2 Diabetes, Metabolic Dysfunction, Cardiovascular Risk, Osteoarthritis, Bone Density, Muscle Loss, Body Composition, Clinical Trials, Phase Three Trials, Injectable Medication, Weight Loss Drug, Pharmaceutical Intervention, Hunger Hormone, Satiety, Nausea, Constipation, Gastrointestinal Side Effects, Compounding Pharmacy, Counterfeit Medication, Obesity Treatment, Incretin Hormone, Retatrutide Weight Loss Results, Third Generation Glp 1 Medication

Murphy's GLP-1 update and how strange this is for Jodi: "I cook for you, we eat together, and you're not so hungry anymore. It's like being with a different person." See omnystudio.com/listener for privacy information.

Send us Fan MailIs weight loss really a matter of willpower—or have we misunderstood the biology behind hunger?Bracha Banayan, FNP-BC, joins Joey Pinz to explore the rapidly evolving world of GLP-1 medications, metabolic health, food noise, cravings, and sustainable weight loss. Drawing from her clinical experience and personal journey, Bracha explains why traditional advice to “eat less and try harder” often fails—and why that failure should not be confused with laziness.The conversation moves beyond weight loss into the brain's reward system and the potential relationship between GLP-1s, alcohol, smoking, shopping, and other compulsive behaviors. Bracha also explains why these medications should never become an excuse to ignore strength training, muscle preservation, nutrition, and lasting habit change.The discussion becomes deeply personal as Bracha shares how remedial classes shaped her persistence, why entrepreneurship taught her difficult lessons about leadership, and how leaving Orthodox Judaism led her toward a broader spiritual path. She also reveals how egg freezing changed her relationship with fear, courage, vulnerability, and regret.This is a provocative conversation about biology, personal responsibility, longevity, identity, and what sustainable transformation truly requires.Top Three Highlights

Send us Fan MailPeptides are everywhere right now—but are they truly the future of women's health, or just another wellness trend?In this episode of It's Hertime, Cody is joined once again by Functional Diagnostic Nutrition Practitioner, women's hormone expert, and peptide educator Bria Gadd. Together, we break down what peptides actually are, how they work in the body, and how to know whether they may be the right tool for you.Together they talk about GLP-1 medications like Semaglutide, Tirzepatide, and Retatrutide—and why using them well involves so much more than simply losing weight. We also explore peptides being used for healing and recovery, mitochondrial health, healthy aging, skin, hair, libido, and hormone support.Most importantly, this conversation isn't about finding another shortcut. Peptides can be powerful tools, but they cannot replace nourishing your body, protecting your muscle, managing stress, getting enough sleep, and building a lifestyle that supports your health.In this episode, we cover:• What peptides are and why they're suddenly everywhere• How peptides differ from hormones and traditional medications• Who may—or may not—be a good candidate• Semaglutide, Tirzepatide, and Retatrutide beyond weight loss• How to protect muscle while using a GLP-1• Peptides for recovery, longevity, skin, hair, and libido• Why lifestyle and nervous-system regulation still matter• Potential risks, side effects, and the importance of medical supervision• How to recognize a trustworthy provider and high-quality source• Where peptide therapy may be headed next in women's medicineCurious about peptides and want personalized guidance? You can learn more about working with Cody here.Want to connect with Bria and learn more from her? Visit Bria's website, follow her on Instagram at @bria_period_whisperer, and explore her coaching programs. You can also listen and subscribe to The Period Whisperer Podcast on Apple Podcasts or Spotify.This episode is for educational purposes only and is not intended to diagnose, treat, or replace individualized medical care.Did you learn something new today? Be sure to subscribe to this podcast and share this episode with all the girls you love. We would appreciate it if you'd also leave us a rating and review on iTunes.Want to join our Mixhers Girl community and keep this conversation going? We'd love to hear your thoughts, feelings and experiences! Join us HERE!Join Mixhers email list and be the first to have access to new products and be the girl in the know!Follow Cody Instagram:@codyjeansanders

Dr. Annette Bosworth, known as Dr. Boz, is a physician, educator, and bestselling author who has become a leading voice in metabolic health and therapeutic nutrition. After witnessing firsthand the limitations of conventional approaches to chronic disease, she began exploring the powerful role of nutrition, fasting, and ketosis in improving health. Through her clinical work and popular educational platform, Dr. Boz helps people understand the science behind metabolic health and turn it into practical, sustainable strategies for everyday life. In this episode, Dr. Brian, Dr. Tro, and Dr. Annette talk about… (00:00) Intro (02:42) A little bit about Dr. Annette and an overview of the research she is working on (11:56) Dr. Annette's research on ketogenic patients and Tirzepatide (21:09) GLP1 non-responders (38:01) Sardine fasting (42:25) Food noise and behavioral change (49:35) Outro For more information, please see the links below. Thank you for listening!   Links:   Please consider supporting us on Patreon: https://www.lowcarbmd.com/   Dr. Annette Bosworth: X: https://x.com/AnnetteBosworth Website: https://bozmd.com/ IG: https://www.instagram.com/drboz_annettebosworthmd/   Dr. Brian Lenzkes:  Website: https://arizonametabolichealth.com/ Twitter: https://twitter.com/BrianLenzkes?ref_src=twsrc^google|twcamp^serp|twgr^author   Dr. Tro Kalayjian:  Website: https://toward.health Twitter: https://twitter.com/DoctorTro IG: https://www.instagram.com/doctortro/   Toward Health App Join a growing community of individuals who are improving their metabolic health; together.  Get started at your own pace with a self-guided curriculum developed by Dr. Tro and his care team, community chat, weekly meetings, courses, challenges, message boards and more.    Apple: https://apps.apple.com/us/app/doctor-tro/id1588693888  Google: https://play.google.com/store/apps/details?id=uk.co.disciplemedia.doctortro&hl=en_US&gl=US Learn more: https://toward.health/community/

Welcome to A Friend for the Long Haul - A Long Covid Podcast! This is the last season 4 episode. I'll be taking a break for a few weeks. Season 5 is going to be about friendship, sex, and relationships and I've already lined up a lot of coaches and therapists who have long covid so we can tap their brains and get some insights. I'm so excited about it!For our season finale, I brought together two lovely people who are actively changing how medicine and research treat chronic illness: Dr. Wes Ely and Dr. Julia Moore Vogel. Sadly, we did have some technical issues and I don't have any video for Dr. Julia, and only got 15 of the 30 minutes of Dr. Ely's audio. Nevertheless, we persist. Dr. Ely joined me first to talk about whole-person care, what he learned from decades in the ICU, and his work leading the REVERSE-LC trial. Then, Dr Julia and I dive into what it means to be both a scientist leading research at Scripps, specifically studying repurposed tirzepatide in the Long COVID Treatment Trial-Tirzepatide (LoCITT-T) trial, and someone navigating Long COVID in real time. She shared something early in our talk that hit me deeply: as patients with limited energy, we do not have to spend our precious reserves trying to convince the wrong doctor when we could be looking for the right one.We talk about step counts as real data, pacing without shame, the emotional toll of medical appointments, and the quiet joy of being able to crochet and craft again after years of visual and cognitive limits.We also get into what it really means to be a "refined badass" when your body is struggling.Thank you so much for being here with me this season. If this episode brought you comfort or clarity, please share it with a friend who needs to feel seen.Timestamps:00:00 - The "refined badass" shirt reveal & opening02:03 - Introducing Dr. Julia Moore Vogel & Dr. Wes Ely03:33 - Why human stories matter in medicine & Janet Keith's story06:00 - Julia's work on the Lockett trial (repurposed tirzepatide)11:53 - Dr. Ely on what doctors miss about Long COVID & infection-associated illness17:57 - Finding the right doctor vs. convincing the wrong one24:35 - What the tirzepatide trial is trying to answer38:17 - How Julia protects her energy and avoids crashes53:28 - Step counts, pacing, and quiet wins56:21 - Crocheting again after years of limits & closing reflectionsTo support me and my work:I have an Amazon wishlist that's totally unhinged and has items to help me, our neurospicy and disabled home of 6, and the pup.Check out my snarky long covid merch shop. I don't keep this money, I filter it into community care and donations to supportive orgs. Follow me on Instagram, TikTok, or Substack. But the biggest way you can support me listening, sharing, liking, and recommending the podcast. Thank you!

The NACE Journal Club with Dr. Neil Skolnik, provides review and analysis of recently published journal articles important to the practice of primary care medicine. In this episode Dr. Skolnik and guests review the following publications:1. Pharmacogenomic-informed antidepressant prescribing for moderate-to-severe depressive symptoms in Australian general practice (PRESIDE)– Lancet Primary Care 2026. Discussion by:Guest:Jessica Stieritz, MD Resident - Abington Family Medicine Residency ProgramJefferson Health2. Evaluating movement breaks as a public health strategy to mitigate the harms of prolonged sitting: a large-scale pragmatic intervention British Journal Sports Med 2026. Discussion by:Guest:Neil Skolnik, MDProfessor of Family and Community MedicineSidney  Kimmel  Medical College Thomas Jefferson UniversityAssociate Director - Family Medicine Residency ProgramJefferson Health – Abington3. Tirzepatide and the risk of atherosclerotic cardiovascular events: population based cohort study– BMJ 2026 Discussion by:Guest:Steven Leonard, MD Resident - Abington Family Medicine Residency ProgramJefferson HealthMedical Director and Host, Neil Skolnik, MD, is an academic family physician who sees patients and teaches residents and medical students as professor of Family and Community Medicine at the Sidney Kimmel Medical College, Thomas Jefferson University and Associate Director, Family Medicine Residency Program at Abington Jefferson Health in Pennsylvania. Dr. Skolnik graduated from Emory University School of Medicine in Atlanta, Georgia, and did his residency training at Thomas Jefferson University Hospital in Philadelphia, PA. This Podcast Episode does not offer CME/CE Credit. Please visit  http://naceonline.com to engage in more live and on demand CME/CE content.

Thinking about trying a GLP-1 but not sure if you need a full dose? What exactly is microdosing, and does it really work? In this episode, I'm joined by Dr. Tyna Moore to talk about GLP-1s, microdosing, weight loss, muscle loss, menopause, hormone replacement therapy, and what's next for peptide therapy.

GLP-1 medications like Ozempic, Wegovy, Zepbound, and Mounjaro have reshaped the weight-loss landscape almost overnight — but the way they're often prescribed leaves people under-fueled, losing muscle, and going it alone. In this episode of The Coaching Lab, host Leigh Baker sits down with National Board Certified Health & Wellness Coach Erin Chain and triple-board-certified physician Dr. Sheri Poznanovic of Optin Health & Nutrition to unpack what's really happening in the GLP-1 era — and where health and wellness coaching fits into the care plan.Together they explore why so many people on GLP-1s aren't eating or hydrating enough, how rapid weight loss can mask dangerous muscle mass loss, and why a "prescribe-and-disappear" model falls short. Dr. Poznanovic explains the multidisciplinary approach the Obesity Medicine Association recommends — combining medication, nutrition, body composition testing, VO2 max assessment, and coaching — while Erin shares real-world stories of clients navigating low energy, food noise, protein gaps, medication interactions, and the stigma of being on a GLP-1.Whether you're a coach, a clinician, an employer weighing GLP-1 coverage, or someone considering these medications yourself, this conversation offers a grounded, human look at doing weight loss in a way that protects strength, health span, and quality of life — not just the number on the scale.In this episode: • Why coaching alongside a GLP-1 changes outcomes • The under-eating and muscle-loss risks no one warns you about • Protein targets, carbs, and why "anti-carb" advice backfires • Body composition and VO2 max testing in weight management • Medication interactions as you lose weight • Navigating stigma and the joy of food • What employers and coaches should know before adding GLP-1sCoaches: Explore CE credits at catalystcoachinginstitute.com Employers: Learn about Catalyst Coaching's GLP-Whole offering — results@catalystcoaching360.com Join us this fall at the Rocky Mountain Coaching Retreat & Symposium: catalystcoachinginstitute.com/retreatInfo re earning your health & wellness coaching certification, annual Rocky Mountain Coaching Retreat & Symposium & more via https://www.catalystcoachinginstitute.com/ Best-in-class coaching for Employers, EAPs & wellness providers https://catalystcoaching360.com/Tap into the home of the (freely available) Not Done Yet! articles on unlocking life's 2nd half here.YouTube Coaching Channel https://www.youtube.com/c/CoachingChannelContact us: Results@CatalystCoaching360.comTwitter: @Catalyst2ThriveWebsite: CatalystCoaching360.comIf you are a current or future health & wellness coach, please check out our Health & Wellness Coaching Community on Facebook: https://www.facebook.com/groups/278207545599218.  This is a wonderful group if you are looking for encouragement, ideas, resources and more. 

Is gaining weight really the worst thing that can happen?Obviously, there are a million worse things. But for me, the answer is still kind of yes—and not because of the number on the scale.At my highest weight, the biggest loss wasn't clothing size or how I looked. It was my quality of life. My anxiety got worse. I dealt with agoraphobia and depression. I avoided things, sat on the sidelines, and slowly made my world smaller.After gaining a few pounds back this summer, I had a wake-up call. I'm nowhere near where I was, but I also know I never want to go back to living that way.This episode is about what weight gain can quietly take from you—and why I'm choosing to stop that slide now.Irresistible Links:Show Notes

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant advancements and regulatory milestones that underscore the industry's commitment to addressing complex health challenges with innovative therapeutics and strategic investments. Eli Lilly has achieved a major breakthrough with the FDA approval of Mounjaro (tirzepatide), a dual GLP-1/GIP agonist designed to reduce cardiovascular risks in individuals with type 2 diabetes. This marks a pivotal step forward in diabetes management, as it not only improves glycemic control but also offers cardiovascular protection. The approval of tirzepatide highlights the therapeutic potential of dual agonists in metabolic disorders, setting a new standard for diabetes care. This development places Eli Lilly at the forefront of incretin-based therapies, a crucial advancement given the high cardiovascular risk associated with diabetes. Priovant Therapeutics has secured its first FDA approval for Lisraya (brepocitinib), a novel TYK2/JAK1 inhibitor tablet aimed at treating dermatomyositis, an autoimmune condition characterized by muscle inflammation and skin rash. As a first-in-class therapeutic option, brepocitinib underscores the growing focus on targeted therapies that modulate specific pathways involved in autoimmune diseases. Priovant's success, following its acquisition from Pfizer, signals its emergence as a significant player in rare disease treatment. Bristol Myers Squibb is making waves with a $173 million investment to construct a second radiopharmaceutical manufacturing facility in Indiana. This strategic move aligns with the increasing demand for precision oncology treatments that utilize radiolabeled compounds for targeted cancer therapy. BMS's investment demonstrates a strong commitment to advancing personalized medicine and meeting future demands in this rapidly evolving field. Gilead Sciences has received FDA approval for Bixlenvo (bictegravir/lenacapavir), an integrase/capsid inhibitor combination pill for virologically suppressed HIV patients. This small molecule therapy offers a potent antiviral strategy by combining two mechanisms of action—integrase inhibition and capsid disruption—enhancing long-term viral suppression for HIV patients. This represents an evolution in HIV treatment, promising improved adherence and patient outcomes. In China, Hutchmed's Atled (fanregratinib) has been approved by the NMPA for treating FGFR2-fusion intrahepatic cholangiocarcinoma after successful Phase 2 trials. Fanregratinib exemplifies precision medicine's approach by targeting specific genetic alterations driving cancer progression, offering new hope for patients with this challenging condition. Cytokinetics has reported promising Phase 3 results for Myqorzo (aficamten) in non-obstructive hypertrophic cardiomyopathy. Aficamten acts as a cardiac myosin inhibitor, representing a novel therapeutic avenue that directly targets the underlying pathophysiology of this rare heart disorder. The positive outcomes from these trials support its bid for FDA approval and could expand treatment options significantly. In respiratory disease research, Generate Bio's GB-0895 has shown encouraging Phase 1 biomarker reductions in chronic obstructive pulmonary disease (COPD). This monoclonal antibody approach targets TSLP and marks progress in developing new therapies for respiratory diseases with high unmet needs. Teva Pharmaceuticals has positioned itself as the stalking horse bidder for BioXcel Therapeutics' neuroscience portfolio amid bankruptcy proceedings. Teva's bid highlights ongoing consolidation trends within the pharmaceutical industry as companies seek to bolster their portfolios through strategic acquisitions. Roche's Genentech announced a substantial deal with DualityBio worth over $1 billion for antibody-drug conjugates (ADCs), focusing on developing treatments for cancers resistant to existing ADC therapies. This partnership showcases Roche's commitment to addressing complex oncology challenges through innovative modalities. Furthermore, AusperBio has secured $120 million in series C funding to advance its oligonucleotide therapy for chronic hepatitis B through Phase 3 trials. Such funding milestones demonstrate robust investor confidence and highlight promising advancements in oligonucleotide therapeutics for chronic infections like hepatitis B. These scientific advancements highlight the dynamic landscape of the biotech and pharmaceutical industries, characterized by innovation-driven solutions across various therapeutic areas. The emphasis on targeted therapies, precision medicine, and strategic investments underscores the sector's dedication to enhancing patient care through cutting-edge science and technology. As these developments unfold, they hold significant potential to impact treatment paradigms, offering hope for improved outcomes across various diseases with high unmet needs. The industry's focus on cutting-edge research and strategic collaborations continues to drive innovations that could redefine therapeutic landscapes globally. Thank you for tuning into Pharma Daily—your source for reliable updates on the evolving world of pharmaceuticals and biotechnology. Join us next time as we continue to explore groundbreaking advancements shaping patient care worldwide.Support the show

Semaglutide, tirzepatide and retatrutide are often spoken about as though they are simply different versions of the same thing. They are not—and Kim Constable's personal experience with each one was very different. In this episode, Kim moves beyond receptor science and shares what exploring all three compounds was actually like for her: the benefits she noticed, the side effects she experienced, the results that surprised her and which option she personally preferred. Kim's interest in GLP-1s originally extended far beyond weight loss. As she moved further into menopause, she was struggling with persistent gluteal tendinopathy, joint pain, digestive discomfort, bloating, morning headaches, brain fog, broken sleep and repeated nighttime bathroom trips. Foods she had eaten comfortably for years—including beans, lentils and cruciferous vegetables—had become increasingly difficult to tolerate. After hearing GLP-1s discussed in relation to inflammation, digestion, sleep and metabolic health, Kim began exploring semaglutide. She later tried tirzepatide and retatrutide, allowing her to compare her personal response to all three. The compounds target different combinations of pathways: • Semaglutide primarily targets GLP-1 • Tirzepatide targets GLP-1 and GIP • Retatrutide targets GLP-1, GIP and glucagon Kim explains why those differences matter and why a compound that feels transformative for one person may feel far less effective—or create more unwanted effects—for another. Inside this episode: • Why Kim first became interested in GLP-1s during menopause • The difference between semaglutide, tirzepatide and retatrutide • Why more receptor activity does not automatically mean better results • Kim's personal experiences with appetite and food noise • The differences she noticed in inflammation and physical pain • Changes she observed in digestion, headaches, brain fog and sleep • How each experience affected fat loss and weight maintenance • Why she initially felt hesitant to admit that easier fat loss appealed to her • The judgment surrounding GLP use • Fatigue, headaches and digestive slowing • An unexpected herpes flare-up pattern Kim noticed while taking semaglutide • Why anecdotal observations do not prove clinical causation • The benefits that felt meaningful to Kim and the effects that did not • Which of the three she personally preferred • Why another person's experience or dose should never become your protocol This episode is not intended to tell listeners which compound they should choose. It is a candid account of Kim's individual experience with three different compounds and why she believes the decision is far more nuanced than simply asking which one is “strongest.” This episode contains candid discussion of genital herpes, digestive symptoms and medication side effects. Kim's experience is personal. Nothing discussed should be treated as proof that another person will experience the same benefits, risks or side effects. This podcast is for educational and informational purposes only. Kim is not a doctor or licensed medical practitioner. Nothing in this episode should be interpreted as medical advice, a diagnosis, prescribing guidance or instructions for purchasing, reconstituting, dosing or administering any compound. Always consult an appropriately qualified healthcare professional before beginning, stopping or changing any medication or treatment. Some compounds discussed may be prescription medicines or investigational products depending on jurisdiction and current regulatory status. ✨ Follow Kim Constable online for more real talk and daily motivation:

Who on the team is on a GLP1 medication, why they started it and how's it going? An honest discussion. See omnystudio.com/listener for privacy information.

Everyone in this market is optimizing for the wrong thing. Consumers want the most weight loss for the cheapest price, and up to 40% of what they're losing is muscle.My guests this week are Nicholas Syhler, a former cardiologist who left his residency to work upstream of the heart attacks he was treating, and Paul Elsass, an exercise physiologist who spent years in startup land before landing on the one root cause nobody had solved. Their company, Embla, runs a coach-first GLP-1 program out of Copenhagen with peer-reviewed data on almost 5,000 patients showing 55% less medication and the same weight loss outcomes seen in clinical trials.We get into why the drug was never designed to shut off hunger, why members can sit on a quarter milligram of semaglutide for months instead of escalating every 30 days, and the claims data suggesting aggressive dosing is quietly driving up MSK spend. We also cover why they built the model around self-funded employers rather than direct-to-consumer, what one bundled price under $500 a month actually includes, and their plan to move from weight loss into full cardiometabolic care with deprescribing as the goal.If you're evaluating a GLP-1 strategy for 2027, this one reframes the question. Tune in."We were seeing four to six pounds per week. That's way too much. It should be one to two." — Nicholas SyhlerThank you to our 2026 sponsors!ParetoHealth: ParetoHealth empowers midsize employers with a long-term solution to reduce volatility and lower overall health benefits costs. Visit https://www.paretohealth.com/fully-insured-vs-self-funding-with-paretohealth-spencer-podcast/?utm_source=youtube&utm_medium=referral&utm_campaign=SelfFundedwSpencer to learn more.Samaritan Fund: A program that connects those who need help to the support they need. We are proud to offer the Samaritan Fund Program. Visit SamaritanFundProgram.com to learn more.Vālenz Health: We're Vālenz Health, your partner in improving health literacy, reducing plan spend, and delivering high-value healthcare. Visit ValenzHealth.com to learn more.Imagine360: Imagine360 helps self-funded employers save on healthcare with smarter health plans. Cut expenses by 20-30% with custom solutions. Contact us today at Imagine360.com.Chapters:(00:00:00) Intro: Meet Embla(00:01:30) From Cardiology Residency to Quitting Medicine(00:05:56) Reading the First Line on the Label(00:07:07) Losing Weight Too Fast: The Muscle Problem(00:08:34) Why "Eat Less, Move More" Fails(00:12:43) Coach First, Clinician Second(00:14:19) A Quarter Milligram for Four Months(00:16:52) Semaglutide vs. Tirzepatide(00:19:29) The MSK Claims Nobody Saw Coming(00:22:17) Why Self-Funded Employers, Not Consumers(00:25:09) Where the Name Embla Comes From(00:27:28) One Price, Everything Included(00:30:42) Learning About PBMs the Hard Way(00:34:43) Deprescribing and Cardiometabolic Care(00:42:30) Why America Makes This Harder(00:46:30) The Three Behavioral Levers(00:49:27) How the Program Actually Rolls Out(00:54:14) Diet, Fasting, and Food Quality(00:57:10) The Moonshot(01:00:59) Closing ThoughtsKey Links for Social:@SelfFunded on YouTube for video versions of the podcast and much more - https://www.youtube.com/@SelfFundedListen/watch on Spotify - https://open.spotify.com/show/1TjmrMrkIj0qSmlwAIevKA?si=068a389925474f02Listen on Apple Podcasts - https://podcasts.apple.com/us/podcast/self-funded-with-spencer/id1566182286Follow Spencer on LinkedIn - https://www.linkedin.com/in/spencer-smith-self-funded/Follow Spencer on Instagram - https://www.instagram.com/selffundedwithspencer/

Everyone in this market is optimizing for the wrong thing. Consumers want the most weight loss for the cheapest price, and up to 40% of what they're losing is muscle.My guests this week are Nicholas Syhler, a former cardiologist who left his residency to work upstream of the heart attacks he was treating, and Paul Elsass, an exercise physiologist who spent years in startup land before landing on the one root cause nobody had solved. Their company, Embla, runs a coach-first GLP-1 program out of Copenhagen with peer-reviewed data on almost 5,000 patients showing 55% less medication and the same weight loss outcomes seen in clinical trials.We get into why the drug was never designed to shut off hunger, why members can sit on a quarter milligram of semaglutide for months instead of escalating every 30 days, and the claims data suggesting aggressive dosing is quietly driving up MSK spend. We also cover why they built the model around self-funded employers rather than direct-to-consumer, what one bundled price under $500 a month actually includes, and their plan to move from weight loss into full cardiometabolic care with deprescribing as the goal.If you're evaluating a GLP-1 strategy for 2027, this one reframes the question. Tune in."We were seeing four to six pounds per week. That's way too much. It should be one to two." — Nicholas SyhlerThank you to our 2026 sponsors!ParetoHealth: ParetoHealth empowers midsize employers with a long-term solution to reduce volatility and lower overall health benefits costs. Visit https://www.paretohealth.com/fully-insured-vs-self-funding-with-paretohealth-spencer-podcast/?utm_source=youtube&utm_medium=referral&utm_campaign=SelfFundedwSpencer to learn more.Samaritan Fund: A program that connects those who need help to the support they need. We are proud to offer the Samaritan Fund Program. Visit SamaritanFundProgram.com to learn more.Vālenz Health: We're Vālenz Health, your partner in improving health literacy, reducing plan spend, and delivering high-value healthcare. Visit ValenzHealth.com to learn more.Imagine360: Imagine360 helps self-funded employers save on healthcare with smarter health plans. Cut expenses by 20-30% with custom solutions. Contact us today at Imagine360.com.Chapters:(00:00:00) Intro: Meet Embla(00:01:30) From Cardiology Residency to Quitting Medicine(00:05:56) Reading the First Line on the Label(00:07:07) Losing Weight Too Fast: The Muscle Problem(00:08:34) Why "Eat Less, Move More" Fails(00:12:43) Coach First, Clinician Second(00:14:19) A Quarter Milligram for Four Months(00:16:52) Semaglutide vs. Tirzepatide(00:19:29) The MSK Claims Nobody Saw Coming(00:22:17) Why Self-Funded Employers, Not Consumers(00:25:09) Where the Name Embla Comes From(00:27:28) One Price, Everything Included(00:30:42) Learning About PBMs the Hard Way(00:34:43) Deprescribing and Cardiometabolic Care(00:42:30) Why America Makes This Harder(00:46:30) The Three Behavioral Levers(00:49:27) How the Program Actually Rolls Out(00:54:14) Diet, Fasting, and Food Quality(00:57:10) The Moonshot(01:00:59) Closing ThoughtsKey Links for Social:@SelfFunded on YouTube for video versions of the podcast and much more - https://www.youtube.com/@SelfFundedListen/watch on Spotify - https://open.spotify.com/show/1TjmrMrkIj0qSmlwAIevKA?si=068a389925474f02Listen on Apple Podcasts - https://podcasts.apple.com/us/podcast/self-funded-with-spencer/id1566182286Follow Spencer on LinkedIn - https://www.linkedin.com/in/spencer-smith-self-funded/Follow Spencer on Instagram - https://www.instagram.com/selffundedwithspencer/

What actually happens to a patient a year into real, supervised peptide therapy? In the final episode of our peptides series, Dr. Melissa Jones and host Jamie Preston close the loop on the story that opened this whole series — and get honest about what changed, what didn't, and what every provider and patient still needs to know. This episode goes beyond the science into the human side of the story: what it actually feels like when chronic pain resolves, when weight loss becomes life-changing rather than cosmetic, and when a skeptical clinician becomes one of the most passionate advocates in the building. Jamie also shares his own journey — turning 50, managing diabetes, and reaching his goal weight — as a real example of what supervised, responsible care can look like over time. In this episode, you'll hear: An update on the chronic pain patient from Episode 1 — where he is now, and what's kept his results sustainable What the actual clinical data shows about supervised BPC-157 therapy, and where its limits are Why GLP-1 success is about far more than the number on the scale — confidence, mobility, and mental health The advice Dr. Jones gives new providers who feel nervous bringing up peptides with patients The single biggest myth about peptides she wants to put to rest for good The three things every patient should understand before they ever start a peptide This is the episode that ties the whole series together — not as a sales pitch for peptides, but as a case for doing this the right way, with the right people, for the right reasons. It's the last episode in this run, but it won't be the last time we talk about this. www.YourHealth.Org

Have you experienced False Hope Syndrome? Without telling you exactly what that is, I'm going to let you know chances are good that you have. I have certainly done so in more than one area of my life! False Hope Syndrome runs rampant in relation to weight loss. Listen in, learn exactly what it is and how to keep yourself safe from falling into the disappointment associated with False Hope Syndrome as you move forward in losing and maintaining weight loss.The Weight Loss Winformation Podcast gives you essential psychological information to help you lose weight and more importantly, to help keep you at a healthy weight for your body! No matter how you are working to lose weight and no matter how much weight you want to lose, Weight Loss Winformation will keep you moving in a positive direction. Let's get started because well… Why Weight? (get it? Pun intended… )?Resources:·      BariAfterare: www.bariaftercare.com·      Connie Stapleton PhD website: www.conniestapletonphd.com·      BariAftercare website: https://www.conniestapletonphd.com/bariaftercare·      BariAftercare Facebook page (for members only): https://www.facebook.com/groups/BariAftercare·      Kevin Stephens: Your Bariatric Buddy   https://www.facebook.com/groups/yourbariatricbuddy/people·      Instagram: @ (Caleshia Haynes)·      Instagram: @therealbariboss (Tabitha Johnson)·      Instagram @drsusanmitchell (Dr. Susan Mitchell)·      Instagram: @lauraleepreston (Laura Preston)·      ProCare Vitamins (10% off with code ConnieStapleton)·      Rob DiMedio: https://www.busybariatrics.com/·      Dr. Joan Brugman: drjbrugman@outlook.com·      Dr. Nestor de la Cruz-Munoz on Linked In: https://www.linkedin.com/in/drdelacruzmunoz/From: How Much Weight Will You Lose After Bariatric Surgery? Nestor de la Cruz-Munoz MD, FACS, DABOMJuly 12, 2026 The Evidence Is Clear — And It's Not What Most Patients Expecto    The AACE/TOS/ASMBS guidelines are explicit: Very few preoperative factors are sufficiently predictive to give a precise individual weight loss number.This means the honest answer is not a number — it's a range.The Real Weight Loss Ranges by ProcedureThe most reliable metric is total weight loss percentage (TWL) — not excess weight loss.Sleeve Gastrectomy (SG)·       23–25% TWL at 1 year·       17–19% TWL at 5 years·       PCORnet (65,000+ patients): 18.8% TWL at 5 yearsRoux‑en‑Y Gastric Bypass (RYGB)·       28–31% TWL at 1 year·       21–26% TWL at 5 years·       20–27% TWL at 10 years·       PCORnet: 25.5% TWL at 5 years·       SM‑BOSS RCT: 27.5% TWL at 10 yearsOne‑Anastomosis Gastric Bypass (OAGB)·       Highest early TWL·       Emerging evidence suggests greater long‑term durability than SG and RYGB·       Randomized TrialsBy‑Band‑Sleeve RCT (3‑year outcomes):·       RYGB: 26.8% TWL·       Sleeve: 19.4% TWL·       Band: 14.0% TWLWeight regain after cessation of medication for weight management: systematic review and meta-analysiso   West S, Scragg J, Aveyard P, Oke JL, Willis L, Haffner SJP, Knight H, Wang D, Morrow S, Heath L, Jebb SA, Koutoukidis DA. Weight regain after cessation of medication for weight management: systematic review and meta-analysis. BMJ. 2026 Jan 7;392:e085304. doi: 10.1136/bmj-2025-085304. PMID: 41500720; PMCID: PMC12776922.o   https://pubmed.ncbi.nlm.nih.gov/41500720/·       The primary anti-obesity medications (AOMs) highlighted in this high-level study are newer incretin mimetics, specifically:o   Semaglutide (a GLP-1 receptor agonist)o   Tirzepatide (a GIP/GLP-1 receptor co-agonist)The Rebound Effect: High-Level EvidenceThis January 2026 systematic review and meta-analysis published in The BMJ synthesized data from 37 studies involving 9,341 participants, providing robust, high-level clinical evidence on what happens after stopping these medications:·       Rapid Return to Baseline: On average, patients return to their baseline weight within 1.7 years after stopping any weight management medication.·       Accelerated Regain for GLP-1/GIP Drugs: For those stopping semaglutide or tirzepatide, the rebound is even faster—returning to baseline weight in just 1.5 years.·       Faster than Behavioral Programs: The rate of weight regain after medication cessation is significantly faster than the regain observed after finishing behavioral weight management programs.·       Reversal of Health Benefits: Stopping these therapies also rapidly reverses their positive, beneficial effects on cardiometabolic markers.·       These findings emphasize that using these medications short-term without a more comprehensive, long-term approach to weight management leads to a rapid reversal of both weight loss and cardiometabolic improvements, and this is the real benefit we can offer to our patients: a long-term plan that can and should be updated on the course of their chronic disease and its natural course. Nothing in obesity treatment should be absolutely static.·      How to overcome past dieting failures. By Kristen A. Carter MSo   https://www.psychologytoday.com/us/blog/health-and-human-nature/202103/false-hope-syndrome-reveals-big-problem-dieting·      Getting Real: Warning Signs of False Hope Syndrome. by Dan J. Tomasulo PhD., TEP, MFA, MAPPo   https://www.psychologytoday.com/us/blog/the-healing-crowd/202209/getting-real-warning-signs-of-false-hope-syndrome·      Expected Weight Loss From Gastric Bypass – Calculatoro   https://www.obesitycoverage.com/weight-loss-surgeries/gastric-bypass/how-much-can-i-expect-to-lose·      Expected Weight Loss (after Sleeve)o   https://www.obesitycoverage.com/gastric-sleeve-reference-manual/

Two experts in obesity medicine discuss the latest advances in obesity care, including: Current data for incretin-based therapies Beyond the scale—individualizing OMM selection based on weight-related comorbidities and cardiometabolic risk Common contraindications and warnings associated with certain OMMs Shared decision-making strategies to inform treatment selection. [JF1]Added this to the episode notes to maybe help with the posttest  Presenters Amy Butts, PA-C, DFAAPA, BC-ADM, CDCES Endocrine Physician Associate WVU Medicine Wheeling Hospital Immediate Past President of American Society of Endocrine Physician Associates Wellsburg, West Virginia Nicholas Pennings, DO Professor of Family Medicine Campbell University School of Osteopathic Medicine Director of Clinical Education Obesity Medicine Association Buies Creek, North Carolina Link to full program:https://bit.ly/4v7eIY4 Get access to all of our new podcasts by subscribing to the Decera Clinical Education Multispecialty Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

What if the peptide you just ordered online isn't wrong — it's just wrong for you? In Episode 2 of our peptides series, clinical pharmacist Dr. Melissa Jones takes us inside the actual decision-making process providers use to match a peptide to a patient, and why skipping that process is how people end up wasting money, or worse, hurting themselves. Host Jamie Preston and Dr. Jones dig into the real science: what a peptide is, how peptides signal the body, and why a healthy foundation — hormones and gut health — has to come before any peptide is even considered. From there, they cover the wide menu of options (tissue repair, skin and hair, sexual health, growth hormone support, metabolic health, sleep and stress) and what it actually means to “stack” or “cycle” peptides responsibly. In this episode, you'll hear: Why there isn't — and won't be — one peptide that does it all, and what that means for how providers build a plan How stacking and cycling actually work, and where cost becomes a real factor in the decision The difference between FDA-approved peptide uses (like Tesamorelin for visceral fat) and the anecdotal dosing happening across the wellness world The real danger in reconstituting and self-dosing peptides ordered online, explained in plain terms What responsible, supervised GLP-1 (Mounjaro, Ozempic, tirzepatide) therapy looks like — and what goes wrong with compounded, unregulated versions The specific list of patients who should avoid peptides or use extra caution, and why providers need to know it cold If you've ever wondered whether a peptide could actually help you — or wondered what your provider is really weighing before saying yes — this episode gives you the real answer, not the Instagram version. www.YourHealth.Org

You've seen the ads. You've heard the buzz. But do you actually know what peptides are — or what they're doing inside your body? In this first episode of a three-part series, Jamie Preston sits down with Dr. Melissa Jones, a 25-year clinical pharmacist and VP at Your Health, to lay the foundation every patient and provider needs before entering the peptide conversation. Dr. Jones brings rare credibility to this space — she didn't come in as a believer, she came in as a scientist who was challenged to learn, and what she found changed how she practices. What you'll hear in this episode: Why insulin is a peptide — and why that means peptides have been in your medicine cabinet for years How BPC 157 and TB 500 work together to signal the body to heal — and the real patient stories behind that science Why GLP-1 medications like Mounjaro and Ozempic are peptides, and how they actually produce weight loss The difference between peptides and steroids (hint: one sends signals, one messes with your hormones) Why "research use only" labels are a red flag — and why compounding pharmacies matter more than you think What providers need to start asking patients right now Whether you're a patient who's been curious or a provider who's been hesitant, this episode gives you the grounded, evidence-informed starting point you've been looking for. Part two goes even deeper — but this is where it begins. www.YourHealth.Org

Check Out BioVitalis Peptides: https://biovitalis.org/ (Use Promo Code: GSD10 for 10% off)   Check Out Jim Brown's Substack Blog: https://substack.com/@forj   *Disclaimer: This NOT medical advice. Please make sure to seek your own medical professional for medical advice.

You might think the win on a GLP-1 like Ozempic or Mounjaro is the number dropping on your scale, but I need you to ask a better question, not how much you're losing, but what kind. In some studies, 40 to 60% of the weight people lost on these drugs came from lean muscle, not fat, and that's a metabolic loss that costs you your strength and your ability to keep the weight off. These are the most powerful fat-loss tools we've ever had, but a tool without a protocol is just potential. Hit your protein and lift, or you're trading muscle for a number you'll spend years trying to earn back. CLICK HERE TO BECOME GARYS VIP!: https://bit.ly/4ai0Xwg Thank you to our partners A-GAME: “ULTIMATE15” FOR 15% OFF: http://bit.ly/4kek1ij AION: “ULTIMATE10” FOR 10% OFF: https://bit.ly/4h6KHAD AIRES: "ULTIMATE20 " FOR 20% OFF: https://bit.ly/4a3Duze BAJA GOLD: "ULTIMATE10" FOR 10% OFF: https://bit.ly/3WSBqUa BODYHEALTH: “ULTIMATE20” FOR 20% OFF: http://bit.ly/4e5IjsV COLD LIFE: THE ULTIMATE HUMAN PLUNGE: https://bit.ly/4eULUKpCYMBIOTIKA: "BRECKACYM30" FOR 30% OFF: https://bit.ly/4tjyluP GENETIC METHYLATION TEST (UK ONLY): https://bit.ly/48QJJrk GENETIC TEST (USA ONLY): ⁠https://bit.ly/3Yg1Uk9 GOPUFF: GET YOUR FAVORITE SNACK!: https://bit.ly/4obIFDC H2TABS: “ULTIMATE10” FOR 10% OFF: https://bit.ly/4hMNdgg HEALF: 10% OFF YOUR ORDER: https://bit.ly/41HJg6S PEPTUAL: “TUH10” FOR 10% OFF: https://bit.ly/4mKxgcn SNOOZE: LET'S GET TO SLEEP!: https://bit.ly/4pt1T6V WHOOP: JOIN & GET 1 FREE MONTH!: https://bit.ly/3VQ0nzW Watch  the “Ultimate Human Podcast” every Tuesday & Thursday at 9AM EST: YouTube: https://bit.ly/3RPQYX8 Podcasts: https://bit.ly/3RQftU0 Connect with Gary Brecka Instagram: https://bit.ly/3RPpnFs TikTok: https://bit.ly/4coJ8fo X: https://bit.ly/3Opc8tf Facebook: https://bit.ly/464VA1H LinkedIn: https://bit.ly/4hH7Ri2 Website: https://bit.ly/4eLDbdU Merch: https://bit.ly/4aBpOM1 Newsletter: https://bit.ly/47ejrws Ask Gary: https://bit.ly/3PEAJuG Timestamps 00:00 - Intro of Show 00:22 - Weight loss vs fat loss 00:38 - What GLP-1 does in the body 01:02 - Semaglutide: the first generation 01:28 - Tirzepatide and the dual agonist 01:45 - Retatrutide and 24.2% body weight loss 02:20 - Why each added receptor works 02:38 - The hidden cost: protecting lean muscle 03:05 - 60% of weight loss from muscle 03:35 - The two-part fix: protein and training 04:05 - Protein targets and leucine-rich sources 04:30 - Resistance training and compound lifts 05:00 - Use the medication, do the work Disclaimer: This podcast is for informational purposes only and does not provide medical advice. It is not intended for diagnosing or treating any health condition. Always consult a licensed healthcare professional before making health or wellness decisions.  Gary Brecka is the owner of Ultimate Human, LLC which operates The Ultimate Human podcast and promotes certain third-party products used by Gary Brecka in his personal health and wellness protocols and daily life and for which Ultimate Human LLC and / or Gary Brecka directly or indirectly holds an economic interest or receives compensation.  Accordingly, statements made by Gary Brecka and others (including on The Ultimate Human podcast) may be considered promotional in nature. Learn more about your ad choices. Visit megaphone.fm/adchoices

July is the Saturday of summer. Life feels a little lighter, the rules feel looser, and for a minute, you can breathe before August shows up with its deadlines, resets, and Sunday scaries.As I'm getting ready for my birthday trip and trying to soak up the last bit of that July freedom, I've been thinking about how often two things can be true at the same time. I can love the life I've worked so hard to build and still feel overwhelmed. I can be proud of how far I've come in my weight and body image journey and still have days when it feels hard. I can appreciate my body and still want change.In this episode, we're talking about letting go of the all-or-nothing thinking that tells us we have to pick one truth, and making room for the messy, complicated reality of healing, growth, and actually living your life.Irresistible Links:Show Notes

Dr. Mike Hart welcomes Ksenia Petrushkina back for a wide-ranging conversation about using hormones, GLP-1 medications, and peptides more thoughtfully. They explore why lower, individualized doses of tirzepatide may improve tolerability, which blood markers should be monitored during treatment, and how progesterone may support sleep through its effects on GABA. They also discuss women's hormone replacement therapy, personalized testosterone dosing, TRT and fertility, thyroid treatment, low-dose naltrexone, and the difference between evidence-based peptide use and exaggerated online claims. Ksenia Petrushkina is a clinician whose work focuses on hormone optimization, peptide therapy, metabolic health, and highly individualized treatment. Through comprehensive blood testing, symptom assessment, careful dose adjustments, and ongoing patient monitoring, she helps men and women better understand how hormones, medications, and peptides may affect their energy, sleep, inflammation, fertility, body composition, and long-term health. Her approach challenges standardized protocols and social-media biohacking trends, emphasizing personalized medicine, responsible prescribing, and evaluating one intervention at a time.   Quick Coherence Technique — HeartMath https://help.heartmath.com/introduction/quick-coherence-technique/ The Levels of Ghrelin, Glucagon, Visfatin and GLP-1 Are Decreased in the Peritoneal Fluid of Women with Endometriosis — Aleksey M. Krasnyi et al. https://pubmed.ncbi.nlm.nih.gov/36142272/ Women's Health Initiative — National Heart, Lung, and Blood Institute, National Institutes of Health https://www.nhlbi.nih.gov/science/womens-health-initiative-whi Facial Beauty Age Support Serum for Estrogen Deficiency — Quicksilver Scientific https://www.quicksilverscientific.com/products/facial-beauty-serum Peptides: The Science, Uses & Safety — Dr. Andrew Huberman and Dr. Abud Bakri https://www.hubermanlab.com/episode/peptides-the-science-uses-and-safety-abud-bakri Vladimir Khavinson Publications — Professor Vladimir Khavinson https://khavinson.info/publications   Show Notes   00:00 Welcome to the Hart2Heart Podcast 00:57 GLP-1 Starting Doses 03:39 GLP-1 Anti Inflammation Aging 07:15 Motility Supplements Side Effects 09:02 Tirzepatide vs Semaglutide 11:46 Adrenal Fatigue Myth 13:23 Fatigue Bloodwork Checklist 16:16 TRT Hematocrit Sleep Apnea 19:01 Underrated Blood Tests 20:06 Womens HRT Basics 22:21 Testosterone for Women 25:19 Thyroid Treatment LDN NAD 29:31 Progesterone GABA Sleep 32:25 Progesterone for Men Debate 33:43 Testosterone Injection Frequency 36:05 TRT Dosing Frequency 36:45 Why TRT Stops Working 37:50 Creams vs Injections 39:08 Fertility and HCG 41:46 Peptides vs Pharma 44:17 HGH and Secretagogues 45:12 5-Amino-1-MQ Hype 48:15 Topical GHK-Cu Skincare 50:25 Injectable Copper Peptide Hair 52:26 BPC 157 and TB500 58:25 Thymosin Alpha 1 Immunity 01:01:13 Mitochondrial Peptides 01:03:20 Endo 205 and New Peptides 01:04:17 Kavinson and Epitalon 01:08:21 Wrap Up and Where to Find   The Hart2Heart podcast is hosted by family physician Dr. Michael Hart, who is dedicated to cutting through the noise and uncovering the most effective strategies for optimizing health, longevity, and peak performance. This podcast dives deep into evidence-based approaches to hormone balance, peptides, sleep optimization, nutrition, psychedelics, supplements, exercise protocols, leveraging sunlight, and de-prescribing pharmaceuticals — using medications only when absolutely necessary. Beyond health science, we explore the intersection of public health and politics, exposing how policy decisions shape our health landscape and what actionable steps people can take to reclaim control over their well-being. Guests range from out-of-the-box thinking physicians such as Dr. Casey Means (author of "Good Energy") and Dr. Roger Sehult (Medcram lectures) to public health experts such as Dr. Jay Bhattacharya (Director of the National Institutes of Health (NIH) and Dr. Marty Mckary  (Commissioner of the Food and Drug Administration (FDA) and high-profile names such as  Zuby and Mark Sisson (Primal Blueprint and Primal Kitchen). If you're ready to take control of your health and performance, this podcast is for you.We cut through the jargon and deliver practical, no-BS advice that you can implement in your daily life, empowering you to make positive changes for your well-being.   Connect with Dr. Mike Hart Instagram: @drmikehart Twitter: @drmikehart Facebook: @drmikehart

Rick Collins, Esq., NSCA-CSCS, is a lawyer who defends the nutrition and fitness community, a partner at Collins Gann McCloskey & Barry PLLC, and General Counsel to the International Society of Sports Nutrition. Peptides are everywhere right now, but most of what's sold online as BPC-157 or TB-500 is illegal — and the FDA is about to decide what happens next. Rick breaks down the science, the legal gray market, and why the military's new testosterone screening policy matters too. Expect to learn what actually counts as a "peptide," how GLP-1 drugs normalized injectable medications and fueled the gray market, what the FDA's own scientists concluded about BPC-157 and TB-500, why Rick's caseload has shifted from steroids to 80-90% peptide cases, what a possible "experimental peptide" middle-ground category could look like, and what really happens when the FDA raids a peptide seller, and much more. Connect with Rick:www.RickCollins.com Episodes you'll enjoy next: #371 — Peptides, TRT, GLPs & Bloodwork: How to Do It Safely (and What Most People Miss) with John Gorman: Listen here #319 — Exploring the World of Peptides with Anthony Castore: Listen here Episode Timestamps: 4:07 Rick's background as a lawyer and his standard legal disclaimer 6:14 What actually counts as a "peptide" 8:25 How GLP-1 drugs normalized injectable medications 10:44 Loss of trust in the FDA fuels the gray market 11:46 The rise of personal health autonomy 13:40 Two markets: the medical model vs. "bro science" 16:23 Inside the FDA Compounding Advisory Committee meeting 19:23 FDA scientists' verdict on BPC-157 and TB-500 20:49 Why the science on BPC-157 is still so thin 22:07 Prohibition logic: the black market will keep growing 25:47 A possible middle ground: an "experimental peptide" category 32:11 Rick's caseload shift — from steroids to 80-90% peptide cases 35:30 Why big pharma cares about tirzepatide and retatrutide knockoffs 42:28 Pete Hegseth and testosterone screening in the military 46:57 Why the new TRT policy may be "much ado about nothing" 49:23 Low testosterone's real, well-documented health risks 52:26 Richard Dawkins, The Selfish Gene, and biohacking against nature 57:12 The schism between orthodox medicine and biohacking 62:39 What happens when the FDA raids a peptide seller 63:30 Connect with Rick Collins Get the Daily Fitness Insider newsletter (free): https://www.miketnelson.com/newsletter

All Yeptide Resources DianeKazer.com/YEPTIDES Join Our Elite VIP Tribe DianeKazer.com/VIP Apply to Become a 1-on-1 Patient DianeKazer.com/PATIENT After announcing this week's podcast, my inbox exploded. Some of you are considering starting a GLP-1. Others have been taking one for months but aren't seeing the results you hoped for. Many of you asked if there's a way to lose weight without sacrificing muscle, energy, or long-term metabolic health. And one question kept coming up over and over... "Can I support my body while taking a GLP-1?" The answer is yes—and that's exactly what we'll be discussing. The Biggest Misconception About GLP-1s Whether you're taking Retatrutide, Tirzepatide, an oral GLP-1, or simply researching your options, one thing remains true: No medication replaces healthy cells. A GLP-1 can help regulate appetite, improve blood sugar control, and make it easier to lose weight—but it can't single-handedly fix sluggish thyroid function, burned-out mitochondria, poor circulation, chronic inflammation, nutrient deficiencies, or years of accumulated stress. That's why some people feel incredible... While others experience: • Fatigue • Constipation • Muscle loss • Plateaued weight loss • Poor energy • Or regain the weight once they stop. The medication may be working exactly as intended—but the body still needs support. The Questions We'll Answer During the Podcast ❓ Which metabolic therapy is right for me? We'll compare the differences between today's most talked-about metabolic therapies, including: ✔️ Retatrutide ✔️ Oral GLP-1 options ✔️ SLU-PP-332 You'll learn how each works differently, where each may fit, and why there is no universal "best" choice for everyone. ❓ Can I preserve muscle while losing fat? Absolutely—but only if you're intentional. We'll discuss why maintaining muscle is one of the most important predictors of long-term metabolic health and the habits that help protect it, including: ✔️ Protein intake ✔️ Resistance training ✔️ Hydration & electrolytes ✔️ Recovery & sleep ❓ Where do bioregulators fit into all of this? This may be the most exciting part of the conversation. While GLP-1s influence appetite and blood sugar signaling, bioregulators take an entirely different approach. Rather than telling your body to eat less, bioregulators are small naturally occurring peptides that have been studied for their potential to support the normal function of specific organs and tissues. Instead of focusing only on the symptom (weight), they focus on helping the systems that regulate metabolism perform more efficiently. During the podcast, we'll discuss how practitioners are using targeted organ support alongside metabolic therapies to create a more comprehensive strategy for health. We'll explore bioregulators that support the ABSOLUTE ESSENTIALS for ANY weight loss, fat burning and metabolic fixing protocol, with or without GLP's or any peptides Because if the systems responsible for metabolism, muscle building and mitochondrial are struggling... Simply eating less may never address the underlying reasons metabolism slowed in the first place. ❓ Should I stay on a GLP forever? This is another question we'll unpack. For some individuals, long-term therapy may make sense. For others, the goal may be to use these medications as a bridge while rebuilding the foundations of metabolic health through nutrition, movement, muscle preservation, hormone optimization, stress reduction, restorative sleep, and supporting healthy organ function. Every person is different—which is exactly why individualized care matters. My Philosophy Has Never Changed I'm not interested in promoting extremes. I'm not "anti-GLP." I'm also not "GLP-only." The healthiest outcomes rarely come from relying on a single medication, supplement, peptide, or protocol. They come from supporting the entire body. That's why this podcast won't just focus on how to lose weight, since weight is JUST a symptom of a broken bigger, deeper rooted issue. If you've been curious about GLP-1s, wondering whether bioregulators could play a role in your wellness journey, or simply want a more complete understanding of today's metabolic therapies, I think you'll get a tremendous amount from this conversation. I can't wait to share it with you. Everyone's talking about GLP-1s. Almost no one is talking about the organs, mitochondria, and communication systems that ultimately determine metabolic health and why we gain weight to begin with.

Save 20% on all Nuzest Products WORLDWIDE with the code MIKKIPEDIA at www.nuzest.co.nz, www.nuzest.com.au or www.nuzest.comCurranz Supplement: Use code MIKKIPEDIA to get 20% off your first order - go to www.curranz.co.nz  or www.curranz.co.uk to order yours NZ listeners - save 10% off Calocurb by using the code Mikkipedia10 at www.calocurb.co.nzThis week on the podcast Mikki speaks to two researchers, Professor Daniela Hurtado and Dr Regina Castaneda about the interaction between HRT and tirzepatide use. In a conversation led by Regina, they talk about differences that occur as women head through menopause, the role of HRT at mitigating some of these changes and the findings from their paper looking at how hormone therapy might enhance the therapeutic effects of tirzepatide in a postmenopausal population - discussing sex related differences.Maria Daniela Hurtado Andrade, M.D., Ph.D., is from Ecuador where she completed her medical degree at the Pontifical Catholic University. Her curiosity about the causes of obesity led her to pursue doctorate-level training in Physiology and Pharmacology at the University of Florida. Her research focused on the brain's regulation of food intake. After her doctoral training, she completed Internal Medicine training at the University of Pittsburgh Medical Center in Pittsburgh, PA, and Endocrinology Fellowship specialty training at Mayo Clinic in Rochester, MN. She joined Mayo Clinic Staff in 2019.Dr. Hurtado Andrade is interested in understanding obesity's pathophysiology to develop more effective therapeutic interventions. She is part of the Mayo Clinic Precision Medicine for Obesity program. This program aims at developing an individualized approach to the management of obesity and its complications with the goal of improving outcomes. To facilitate the generation of this new knowledge, she has focused her clinical and research efforts on specific populations: perimenopausal women and breast cancer survivors. Dr. Hurtado's contributions and expertise to the field of obesity have been recognized nationally and internationally.Regina Castaneda, MD, serves as a postdoctoral research fellow at Mayo Clinic in Florida. She is also an MSc candidate at Mayo Clinic College of Medicine and Science. Her work centres on women's health topics including obesity, diabetes, and menopause-related metabolic changes.Dr Castaneda has contributed to research examining the effects of tirzepatide on weight loss in postmenopausal women and the potential influence of hormone therapy. She is affiliated with the Division of Endocrinology, Diabetes and Metabolism at Mayo Clinichttps://www.mayoclinic.org/biographies/hurtado-andrade-maria-daniela-m-d-ph-d/bio-20539671https://www.linkedin.com/in/regina-castaneda-md-8b2371358/ Paper: https://www.thelancet.com/journals/lanogw/article/PIIS3050-5038(25)00145-1/abstract Contact Mikki:https://mikkiwilliden.com/https://www.facebook.com/mikkiwillidennutritionhttps://www.instagram.com/mikkiwilliden/https://linktr.ee/mikkiwilliden

As current understandings of obesity (ie, a chronic disease requiring long-term management) are adopted across the world, screening and treatment can no longer follow a one-size-fits-all approach. Listen in as 3 global experts in obesity medicine highlight the emerging evidence from recent conferences that are changing real-world practice today. Learn how the latest findings apply to specific patient populations across the United States, Europe, and Asia as well as why healthcare professionals should individualize treatment based on patient preferences and relevant risk factors. Presenters: Stephano Del Prato, MD Professor Emeritus of Endocrinology University of Pisa Pisa, Italy Soo Lim, MD, PhD Professor of Medicine Department of Internal Medicine Seoul National University College of Medicine and Seoul National University Bundang Hospital Seoul, South Korea Donna H. Ryan, MD Professor Emerita Pennington Biomedical Research Center Louisiana State University New Orleans, Louisiana Link to full program:https://bit.ly/4pwFhEo Get access to all of our new podcasts by subscribing to the Decera Clinical Education Multispecialty Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

A Note from James:I'm doing a big experiment in my life.I recently started taking a GLP-1—tirzepatide, one of the so-called weight-loss drugs. But I didn't start taking it specifically for weight loss. I had some blood work done for the first time in a long time, and there was a small indication that I might be pre-diabetic. My doctor suggested trying tirzepatide, and I wanted to understand what I was getting into.The first person I wanted to talk to was Charles Duhigg, author of The Power of Habit and Supercommunicators. Charles has been taking a GLP-1 for about two years, and he says it has changed his life. He has lost around 45 pounds, but what interested me most was not just the weight loss. It was the habit change.Charles explains that GLP-1s can quiet what people now call “food noise”—the constant background pull toward eating even when you are not actually hungry. When that noise quiets down, something interesting happens: you get a window where your old habits become more malleable.That is the key idea of this conversation. The drug may help you eat less, but the bigger opportunity is that it gives you a chance to build new routines around food, exercise, alcohol, sleep, and identity. And if you build those habits while the window is open, those habits may continue even after you stop taking the medication.We talk about food noise, cravings, the habit loop, keystone habits, stated versus revealed preferences, placebo effects, alcohol, sleep, exercise, blood sugar, identity, and whether GLP-1s are a lifelong drug or a tool for changing who you become.Episode Description:James is at the beginning of a GLP-1 experiment. Charles Duhigg is two years in.In this conversation, Charles explains what he has learned from taking tirzepatide and from studying GLP-1s through the lens of habit formation. He describes the first phase of public understanding around these medications as weight loss. Phase two, he argues, is about behavior change.The central concept is “food noise.” Charles describes it as the background craving that turns a basket of fries into an almost automatic behavior. You may not even notice the noise until it goes away. Once it quiets, the cue that normally triggers the habit loop weakens. That creates a temporary window where new habits can be built.James and Charles use the GLP-1 experience to revisit the basic habit loop: cue, routine, reward. They talk about why habits feel automatic, why willpower is often the wrong tool, and why successful behavior change depends on identifying the cue and replacing the routine while still satisfying the underlying reward.Charles also introduces the idea of GLP-1s as a catalyst for keystone habits. Eating less can make exercise easier. Drinking less can improve sleep. Better sleep can improve focus. Focus can improve work. One changed habit can set off a chain reaction.The conversation then becomes more philosophical: Who are we if one part of the brain says “I want to be healthy,” while another part of the brain keeps revealing different preferences through action? Charles explains the difference between stated preferences and revealed preferences, and how repeated behavior can shift identity.This is not a conversation about taking GLP-1s casually. It is a conversation about using a medical intervention deliberately, under appropriate medical guidance, as a chance to change the patterns that shape daily life.Editorial Note:This episode discusses prescription medications, including tirzepatide and semaglutide, as well as personal experiences with GLP-1 drugs. It should not be treated as medical advice.GLP-1 medications can have side effects and risks, including gastrointestinal symptoms, dosing concerns, and contraindications for some patients. They should be used only under the supervision of a qualified medical professional. Any decision to start, stop, adjust, or combine medications should be made with a clinician.James and Charles also discuss personal experience, habit change, appetite, alcohol cravings, and identity. Individual responses to these medications vary.What You'll Learn:Why Charles believes GLP-1s are entering “phase two”: not just weight loss, but habit change.What “food noise” feels like—and why people often do not notice it until it disappears.How GLP-1s may create a temporary “habit window” where old routines become easier to change.Why the habit loop—cue, routine, reward—matters when trying to change eating behavior.Why people often regain weight after stopping GLP-1s if they have not built new habits.How keystone habits can create a chain reaction across food, exercise, alcohol, sleep, and focus.Why micro habits may work better than a full lifestyle overhaul.How stated preferences and revealed preferences shape identity.Why eating less can make exercise easier, and why exercise can reinforce healthier choices.Why tracking behavior may be essential while taking a GLP-1.How placebo, alter egos, and rituals may influence identity and performance.Why the goal is not just losing weight, but becoming the kind of person whose habits support health.Timestamped Chapters:[03:36] James Begins His GLP-1 ExperimentJames explains his early experience, including confusion between medication side effects and a bout of COVID.[04:16] Charles's Two-Year ExperienceCharles describes taking tirzepatide, losing roughly 45 pounds, and why the biggest changes came months into the process.[05:38] Phase One vs. Phase Two of GLP-1sPhase one was about appetite and weight loss. Phase two, Charles argues, is about habits that can last.[06:42] The Habit WindowHow GLP-1s can quiet food noise and create a period where eating habits become more malleable.[07:21] COVID, Side Effects, and Early SignalsJames explains why his first few weeks were hard to interpret and why he is still figuring out what the medication is doing.[09:00] What Food Noise Actually Feels LikeCharles uses the example of a basket of fries to explain cravings, cues, and automatic eating.[09:55] The Habit Loop: Cue, Routine, RewardCharles revisits the framework from The Power of Habit and applies it directly to food cravings.[10:42] How GLP-1s Interrupt the CueThe fries are still there, but the craving does not activate in the same way.[11:40] What GLP-1s Do in the Body and BrainCharles explains what researchers know about gastric emptying, glucagon-like peptides, and what remains uncertain about the brain.[12:43] What Happens When You StopWhy the medication alone may not be enough if old habits return after discontinuation.[13:36] Pleasure, Food, Alcohol, and AnhedoniaCharles discusses reduced pleasure from food and alcohol, while separating clinical findings from broader claims about losing joy in life.[15:54] Why Charles Stayed With ItEarly changes were not dramatic weight loss, but a growing feeling that eating became more of a choice.[16:40] Eating as a Keystone HabitHow changing food behavior can trigger changes in exercise, alcohol, sleep, focus, and work.[19:31] Why Structure MattersCharles explains why tracking and guided habit systems can help people see patterns they might miss on their own.[20:32] What Changes Physically Over TimeSlower stomach emptying, feeling full longer, more stable blood sugar, and gradual changes in appetite.[21:43] Stated Preferences vs. Revealed PreferencesWhy one part of the brain says “I want to change,” while another part watches what you actually do.[23:22] Identity Change and Habit FormationHow repeated behavior can teach the brain, “I am the kind of person who eats this way” or “I am the kind of person who exercises.”[24:16] Placebo, Belief, and Becoming the Person You Want to BeJames and Charles explore whether placebo effects may work partly by changing identity.[28:07] Alter Egos, Athletes, and RitualsThe conversation turns to Kobe Bryant, Michael Phelps, and how pre-performance routines can cue a desired identity.[29:15] Start With Micro HabitsCharles explains why small behavior changes can compound more effectively than trying to overhaul an entire life at once.[30:40] Charles's First Micro HabitsDrinking less, eating fewer fries, stopping when full, and choosing healthier meals without relying on willpower.[31:24] Feeling Full for the First TimeCharles describes the surprising experience of leaving food unfinished because his body had had enough.[33:03] Why the Stomach ShrinksThe medication does not shrink the stomach directly; eating less over time changes how much food the body expects.[33:21] Why Slower Stomach Emptying HelpsJames asks why a weight-loss drug would slow digestion instead of speeding metabolism.[35:00] The Cumulative EffectWhy the most visible changes often appear after several months, once habits, body size, and identity begin reinforcing each other.[37:03] Is a GLP-1 a Lifelong Drug?Charles explains what research and personal experience suggest about stopping, restarting, and maintaining results.[38:56] James's Health MotivationJames explains that his motivation is not primarily weight loss, but a desire to respond to possible pre-diabetic markers.[39:36] Why Attitude Is Not EnoughCharles argues that wanting to be healthy helps, but habit change still requires structure.[40:02] What Changed at HomeCharles explains how his family's food did not need to change, even though his own choices and portions did.[41:02] Weight, Body Composition, and Pre-DiabetesWhy blood sugar, insulin resistance, fat, and muscle matter more than the scale alone.[42:38] Semaglutide, Tirzepatide, and What Comes NextJames and Charles compare different GLP-1 medications and discuss how newer drugs may work through multiple receptors.[44:27] Will Charles Stop Taking It?Charles explains why he may eventually discontinue the medication, but values having more choice over weight and behavior.[45:24] Blood Work, Snoring, and Health MarkersCharles describes improvements in lab results, cholesterol, snoring, and overall health.[46:31] Who Are We, Really?James and Charles talk about identity, brain chemistry, sugar, alcohol, cravings, and the substances that shape behavior.[48:32] Choosing the Person You Want to BecomeCharles explains how better self-awareness can help people change habits deliberately rather than being pulled by cravings.[49:00] Tracking the ExperimentCharles advises James to track food, feelings, and behavior so he can notice changes that might otherwise be invisible.Additional Resources:Charles Duhigg Official WebsiteThe Power of Habit by Charles DuhiggSupercommunicators by Charles DuhiggNoom's GLP-1 Companion / Habit Formation AnnouncementFDA: Zepbound Approval for Chronic Weight ManagementFDA: Concerns With Unapproved GLP-1 Drugs Used for Weight LossBMJ: Weight Regain After Stopping Weight-Loss MedicationTodd Herman — The Alter Ego EffectSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Cheaper obesity medicines could unlock broader demand, while supply-chain bottlenecks and premium-drug innovation may also shape how the market evolves. Our analysts Terence Flynn and Thibault Boutherin break down the investor implications.Read more insights from Morgan Stanley.----- Transcript -----Terence Flynn: Welcome to Thoughts on the Market. I'm Terence Flynn, Morgan Stanley's U.S. Pharma and Biotech Analyst. Thibault Boutherin: And I'm Thibault Boutherin, Morgan Stanley's Europe Pharmaceuticals Analyst. Terence Flynn: Today, how cheaper GLP-1 obesity medicines could reshape access, pricing, and supply chains; and what the first generic markets may signal for Europe and the U.S. It's Monday, July 13th at 10am in New York. Thibault Boutherin: And it's 3 pm in London. Terence Flynn: Around one billion people live with obesity worldwide, including over a 100 million in the U.S. Right now, the introduction of the first lower cost generics of semaglutide, a GLP-1 medicine, in some international markets, could have consequences on affordability and demand. Thibault, what are the first countries seeing the introduction of sema generics? What are the current dynamics, and why should global investors pay attention? Thibault Boutherin: Sure. So, so far generics are being introduced this year in three countries: in India, Canada and Brazil. And if we look at India, this is the first market where the generics are being introduced. The patent for semaglutide expired in March 2026, and 13 companies have launched 26 generics across different formulations: autoinjectors, vials, and pills, which price is lower than the branded drug. And because the India market was quite under-penetrated for GLP-1, we are seeing affordability driving volume expansion. In Canada, two generics have been launched so far. Four other generics are waiting for approval, and more are being filed. And finally, in Brazil, one generic was approved last month, and we are expecting these generics to be launched in Brazil in July. And 17 other generics are in different stage of regulatory review in Brazil, and we would expect more to enter the market by the end of this year. And the reason why we focus on these markets is because we believe they could provide a blueprint for what could happen later in the U.S. and in Europe; in particular for Canada, which shares some characteristics with Europe and the U.S. And the patent for semaglutide will expire in Europe in 2031 and in the U.S. from 2032. Terence Flynn: Great. Maybe on the India front, I know that's at the leading edge. What happened with patient demand when price came down? Thibault Boutherin: Sure. So, what we saw in India is a surge in volume when generics were launched, and the volume in April 2026 were already six times higher than the volume in February. And that expansion has been driven mostly by these generics launch, which captured 80 percent of semaglutide volume in April. And our India team expect that the GLP-1 market in India will actually expand in value from $125 million in [20]25 to more than $1 billion by 2030, despite lower prices as we see better, you know, greater volume and greater adoption of GLP-1s in India. Terence Flynn: The other thing, you know, you and I have discussed is the supply chain, and one of the questions is the ability of some of the generic manufacturers to scale semaglutide. So, maybe talk to us about the current capabilities. And could we see bottlenecks in the supply chain formation here? Thibault Boutherin: Yeah, sure. So, there are three key elements to watch on the supply chain. The first is the active pharmaceutical ingredient or API, and that's the semaglutide molecule itself. The second element is the device and the device components, and the third element is the fill and finish, which is basically putting all of these things together. On the API side, so semaglutide molecule, we believe there will be no bottleneck in supplying for generics as we see a handful of large Chinese companies, out of China, building multi-ton capacity for semaglutide. So, we believe there will be no shortage of API to supply the generic supply chain for injectables. On the device, these are the same device companies that are supplying the branded version of semaglutide, and other GLP-1s for the device that are also supplying the generic makers. And we are seeing meaningful investments being made, so we don't believe there will be a bottleneck here. Where we could see a bottleneck emerging is on the fill and finish side. Fill and finish requires highly controlled clean room space to minimize contamination. It requires regulatory approval, and it takes up to three years to build fill and finish capacity. And so, that's where if there is not more investment being made over the next few years, there could potentially [be] a bottleneck emerging for the generic companies. Terence, while semaglutide generics will definitely represent a challenge for the existing branded version of this GLP-1, there are some insights in these emerging dynamics that suggest that tirzepatide, the other GLP-1, could be less at risk. Can you touch a bit on some of these dynamics? Terence Flynn: Absolutely. So, just to remind listeners that semaglutide targets a pathway called GLP-1. Tirzepatide actually targets two pathways. The first is GLP-1, and the second is GIP. And there are some data comparing these molecules, both in Type 2 diabetes and obesity. And tirzepatide gives not only better efficacy but also improved tolerability. And so, what you're seeing in some of the ex-U.S. markets is segmentation, where there are some consumers that are willing to pay a premium price for tirzepatide. Our team in Brazil has done a lot of work on this front looking at this dynamic and, you know, we expect that to play out in many geographies. So, despite the entry of lower-cost generic versions, we think you will still see segmentation of the market between differentiated brand and the lower-cost generics. And that as a result, you will continue to see branded growth.In the U.S. right now, market share is about 60 percent in favor of tirzepatide. And so again, you're seeing a differentiation between these two molecules. Thibault Boutherin: And beyond the introduction of generics GLP-1s, there are other dynamics in the industry that are driving this market. And the introduction of oral drugs this year has been a big topic. Terence, what are your views on the role that orals could play on the market? Terence Flynn: Yes, as a lot of people are probably aware, the many of the existing GLP-1 medicines are injectable. And so those are delivered once a week with a needle. But there are now additional oral options of these GLP-1 medicines. They started off first for Type 2 diabetes, but they have now broadened into obesity as well, following some recent FDA approvals. And what we're seeing is that the introduction in the U.S. so far is expanding the market. So, the majority of people that are taking the oral versions of these medicines are new users to GLP-1s. So again, you're getting market expansion. When you think about the orals as well, one of the other questions is capacity. I know, Thibault, you were talking about the supply chain. There are similar questions for these oral medicines because not all of the oral medicines are the same. Some are easier to manufacture than others, and as a result, that's another variable to consider. So, some of these are what's called peptide-based orals, and some of these are non-peptide-based orals. And the non-peptide-based orals are much easier to scale, for a larger global market. And so that's definitely another variable that we're monitoring and that I think investors need to consider. Thibault Boutherin: And beyond the pill versions of these GLP-1s, we are seeing more innovation in the drug pipeline of the industry, which could be a key driver of differentiation against the competition from the generics. So, what are we seeing emerging today from diabetes and obesity pipelines, which could be exciting for the future of the category? Terence Flynn: So, as we see time and time again in pharmaceutical markets, the key players continue to innovate to try to improve profiles of the existing medications. So, there are, you know, kind of two areas. One would be efficacy; another would be safety tolerability. And so, there are a number of players that are working first to develop longer acting medication. So, as I mentioned, the existing injectable drugs are dosed once weekly. But there are a number of companies that are working to develop potentially monthly or less frequent injections. So, that's one area that we're monitoring closely. And then the second, and again, this plays into what I discussed on tirzepatide, is additional pathways that are involved here in diabetes and obesity, and a number of players are working to target additional pathways beyond GLP-1 and GIP. And so, some of the leading pathways that are being studied are something called amylin and glucagon, and there are a number of medications that are in the late-stage pipeline that are coming along, which have some pretty interesting data. And so that's another area that we're watching. And again, the goal there would be to either improve efficacy and/or improve tolerability versus the existing medications. Thibault Boutherin: Great. And maybe we can also take this opportunity to talk about some of the short-term drivers in the market that are not facing generic today, like the U.S. So, what could be, you know, the key drivers for growth of GLP-1s and the overall obesity and diabetes category over the next five years? Terence Flynn: Yeah, obviously the key one is seeing additional uptake of these medicines. I think right now we estimate, again, obesity in particular, there's about low double-digit percent uptake. And so obviously seeing increasing uptake of these medicines. The orals, as I mentioned, are already driving market expansion. And then the third is access. So obviously in any market, that's very important. In the U.S., I think about 50 percent of employers cover these medications right now. We expect that to increase in the years ahead as the data continues to build. But then this year starting very shortly, the patients in the Medicare program in the U.S., so those people over the age of 65, will be able to access these medicines for $50 per month. And so, we think that is another driver of growth – is this will broaden access to about an additional 18 million people, starting this summer. So, the next phase of the diabesity market comes down to execution, lower cost and scaled supply in the mass market, and innovation and differentiation to compete in the premium segment. Thibault, thanks so much for taking the time to talk. Thibault Boutherin: Great speaking with you, Terence. Terence Flynn: And thanks for listening. If you enjoy Thoughts on the Market, please leave us a review wherever you listen and share the podcast with a friend or colleague today.

Is Ozempic secretly slowing down your thyroid? Millions are using GLP-1 medications like Ozempic for weight loss and blood sugar control, but very few people are being warned about what they could be doing to their thyroid health.If you're experiencing fatigue, hair loss, brain fog, cold hands and feet, constipation, or stubborn weight loss plateaus after starting Ozempic, your thyroid may be sending you warning signs that are often overlooked.In this eye-opening episode of Accelerated Health with Sara Banta, I uncover the surprising connection between Ozempic, GLP-1 medications, and thyroid function, why standard thyroid testing may miss the problem, and the essential nutrients your thyroid needs to function properly.If you're taking Ozempic, Wegovy, Mounjaro, or another GLP-1 medication, this is information you don't want to miss.Supplements Featured In This Episode:• Acceleradine® Iodine https://www.acceleratedhealthproducts.com/products/acceleradine-iodine-supplement • Accelerated Liver Care® https://www.acceleratedhealthproducts.com/products/accelerated-liver-care• Accelerated Thyroid® https://www.acceleratedhealthproducts.com/products/accelerated-thyroid-supplement Not sure what food to eat and avoid? This guide is for you.⬇️

In this episode of Girl Talk with Tay, I sit down with Bracha Banayan, family nurse practitioner, entrepreneur, and founder of IVDrips and Hello Dose, for one of our most fascinating conversations yet. We dive into the science behind GLP-1 medications, why they're about so much more than weight loss, and how they're changing the conversation around longevity, metabolic health, and healthy aging.Bracha explains how GLP-1s work in the body, why weight gain is often rooted in biology rather than willpower, and how factors like glucose, insulin, inflammation, and hormones all play a role in long-term health. We also discuss who may benefit from GLP-1 medications, including women navigating perimenopause and menopause, adults focused on cardiovascular health, and those looking to improve metabolic wellness.We also get into fertility, blood sugar, continuous glucose monitors, and the surprising ways GLP-1s may help reduce cravings by working on the brain's reward system. Beyond medications, Bracha shares the foundational habits she believes everyone should prioritize first from walking after meals and getting morning sunlight to improving sleep and building sustainable wellness routines.Whether you're curious about GLP-1s, trying to better understand metabolic health, or looking for practical ways to optimize your health for the long run, this episode is packed with insights and actionable takeaways.xo, Tay⸻Follow Bracha Banayan!

Send us Fan MailCan We Prevent Muscle Loss While Taking GLP-1 Weight-Loss Drugs?GLP-1 medications like Zepbound have changed the way we treat obesity. But as more people lose significant amounts of weight, another question has emerged:What happens to your muscle?It's normal to lose some lean mass—including muscle—during weight loss. But researchers are now asking whether preserving more muscle could improve long-term health, particularly as we age.In this episode, Dr. Eeks speaks with Dr. Richard Pratley, lead author of a new randomized, double-blind, placebo-controlled clinical trial investigating whether an investigational antibody called apitegromab can help preserve lean mass in people taking tirzepatide (Zepbound).Together they discuss:• Why people lose lean mass during weight loss• What "lean mass" actually means—and why it matters• Why muscle preservation has become one of the biggest new questions in obesity medicine• How apitegromab works by blocking myostatin—a protein that acts like a brake on muscle growth• The results of the study and how much lean mass participants preserved• Why preserving lean mass doesn't automatically mean preserving strength• Whether concerns about muscle loss on GLP-1 medications have become exaggerated• The importance of resistance training and adequate protein during weight loss• Whether future obesity treatment will focus less on body weight and more on body composition• The bigger question: Are we entering an era where one medication leads to another—or is there a better path???This conversation explores one of the most interesting—and practical—questions in obesity research today: Can we lose fat without sacrificing too much muscle?Work with me? Perhaps we are a good match. Keep Causes or Cures Ad-Free with Listener SupportYou can contact Dr. Eeks at bloomingwellness.com.Follow Eeks on Instagram here.Follow on X. Or Facebook here.On Youtube.Or TikTok.SUBSCRIBE to her Newsletter here! (the bits not posted on socia media)Support the show

Before EP Description: Learn about the Healing Power of Prolonged Fasting: HEREWhat if losing weight on a GLP-1 drug and losing weight through fasting produce the same number on the scale, but nearly opposite effects inside your cells?Host Dr. Katie Deming believes some of the most popular weight loss drugs on the market may be quietly blocking one of your body's most essential repair processes. Not because they're failing to work, but because they work in a way that keeps your body in a state it was never meant to stay in.She takes an honest, no-shame look at GLP-1 drugs like Ozempic and Wegovy and compares what's actually happening inside your body when you lose weight on them versus when you fast. The scale might show the same number. The story underneath is very different. Dr. Katie explains a repair switch your body can only flip when your stomach is genuinely empty, and why keeping it perpetually fed may keep that switch turned off for good. She connects the dots between mitochondrial health, cellular cleanup, visceral fat, muscle preservation, and metabolic flexibility in a way that's clear, honest, and direct.She's not here to shame anyone taking these medications. She gets why people reach for something that works. But she shares what happened when several of her patients who were certain they'd go right back on the drug after fasting decided they didn't want to, and why.Chapters:00:04:23 - The Food System Is Broken00:06:13 - Your Body Needs Empty Space00:08:24 - GLP-1s May Block Repair Mode00:10:41 - Weight Loss Is Not Healing00:12:26 - What Cancer Cells Feed On00:13:30 - Fasting Changes the Terrain00:17:00 - Cleaning Out Damaged Mitochondria00:18:00 - The Most Dangerous Fat00:20:35 - The Hidden Muscle Loss Problem00:22:20 - Clients Who Were on GLP-1s Before Fasting00:26:06 - Who Should Never Water Fast If you've ever wondered whether weight loss and true healing are actually the same thing, or why one of her patients gained lean mass six weeks after a 14-day water fast, this episode will change how you think about what your body actually needs.Press play and learn why the repair process your body is waiting to run may only start when you finally stop feeding it.Join Dr. Katie's 3-Day Guided Fast, for expert support, daily live calls, and a community to fast alongside: Sign-Up Follow Dr. Katie Deming on InstagramWatch on YoutubeDISCLAIMER: The Born to Heal Podcast  is intended for informational purposes only and is not a substitute for seeking professional medical advice, diagnosis, or treatment. Individual medical histories are unique; therefore, this episode should not be used to diagnose, treat, cure, or prevent any disease without consulting your healthcare provider.A thought-provoking podcast explores cancer through the lens of holistic medicine and functional medicine, discussing causes of cancer, metabolic health, and unconventional approaches like water fasting, fasting and autophagy, and detox, while weighing fasting benefits against chemo side effects and radiation side effects, sharing stories of a cancer survivor navigating chemotherapy, natural medicine, holistic healing, and even spiritual healing on the path toward cancer remission and holistic health. 

Have you ever looked at your life and weight loss journey and felt like nothing is changing?Like one workout doesn't matter. One healthy meal won't make a difference. One act of self-care feels insignificant. In this episode, I'm sharing one of my favorite metaphors: diamond painting.Each tiny diamond seems insignificant on its own. You can't see the finished picture while you're placing them. But over time, those thousands of tiny pieces become something beautiful.The same is true for healing your relationship with food, building confidence, embracing your body, becoming the woman you crave to be, and creating the irresistible life you deserve. If you've been judging yourself before you've had the chance to see the full picture, this episode is your reminder to trust the process.Because you're not just placing diamonds.You're building an irresistible life—one tiny diamond at a time.Irresistible Links:Show Notes

Broadcast from KSQD, Santa Cruz on 7-02-2026: Dr. Dawn devotes the first half of the show to a nuanced defense of GLP-1 receptor agonists, arguing the polarized debate treats obesity as a moral failure rather than a physiological one. She recounts the "Marilyn Monroe dress" moment that transformed semaglutide from diabetes drug into elite cosmetic tool, and pushes back on the puritanical framing that behavior change must be earned rather than pharmacologically enabled—noting we don't apply this logic to antihypertensives or statins. Dr. Dawn catalogs visceral fat as a genuine endocrine organ producing over 17 hormones, most of which drive self-perpetuating growth: leptin (this satiety hormone at high levels disables it's own brain receptor), IL-6, TNF-alpha (blocks insulin), resistin (increases insulin resistance and inflammation), PAI-2 (blocks clot breakdown, raising cardiovascular risk), retinol-binding protein 4 (impairs muscle glucose uptake), chemerin (recruits macrophages and directs fat to the belly), and visfatin. Only adiponectin declines with rising visceral fat. It improves insulin sensitivity, suppresses hepatic gluconeogenesis, and blocks IL-6 . Dr. Dawn describes GLP-1's neurobiological action: receptors in the hypothalamus, brainstem, hippocampus, and mesolimbic reward system, with the drugs quieting the brain's salience network so food loses its intrusive pull. Taste buds shift, sweet and salty become muted, and reward circuits stop firing on cheat foods—creating a window during which behavioral change becomes possible. Dr. Dawn frames group support through self-determination theory (autonomy, competence, relatedness), arguing GLP-1s create the cognitive bandwidth for behavioral programs to succeed. A Tufts study of patients discontinuing after 10% weight loss found those enrolled in behavioral support programs regained about three times less weight than usual-care controls, outperforming even medically-tailored meal plans. Group engagement doubled the time patients stayed on the medication. A November 2025 Nature study piggybacked on deep brain stimulation research at Penn. Electrodes implanted in the nucleus accumbens of post-bariatric patients recorded low-frequency brain activity surges during food-noise episodes on drug free patients. A third participant who started tirzepatide showed complete silencing of that signature—the first direct electrical confirmation that GLP-1s suppresses compulsive food thoughts in the reward center. RNA sequencing of adipose tissue from 25 obese patients before and after bariatric surgery, compared to 24 lean controls, revealed persistent epigenetic changes even after weight loss. Lipid-associated inflammatory macrophages drop but retain some of their pro-inflammatory epigenetics, explaining the well-known slippery slope back to obesity—and why Dr. Dawn suggests GLP-1s may work best as intermittent tools when behavioral maintenance starts slipping. An emailer asks about long-term smoking versus vaping data. Dr. Dawn notes there is no long-term data yet, but short-term evidence shows e-cigarettes contain nicotine, propylene glycol, reactive oxygen species, and nitrosamines, producing spirometry readings similar to mild COPD in otherwise-healthy vapers. Vaping over a year raises stroke relative risk by 1.62 and nearly doubles MI risk, and combining smoking and vaping produces a multiplicative rather than additive harm. Data on cancer will take decades to emerge. Researchers built a functioning underwater breathing apparatus for cockroaches with electrodes attached to brain and sensory organs allowing remote-controlled direction while preserving natural obstacle-navigation autonomy. The 10mm × 10mm sponge-based oxygen tank uses magnesium dioxide catalyzing hydrogen peroxide breakdown, delivering oxygen through silicone tubes to the roach's spiracles for up to three hours underwater. Deployemenet will improve search-and-rescue in flooded and collapsed structures where dogs cannot reach. A Science Advances paper from Yong Lin Kong's lab at Rice University describes 3D-printing electronic circuits directly onto living tissue. Researchers achieved microwave-focused annealing at sub-200-micrometer resolution. By selectively heating only conductive ink particles (copper, silver, gold) without damaging surrounding tissue, the technique enables printing circuits onto 3D-printed heart valves, tracheas, and ear scaffolds, potentially creating combined graft-and-sensor implants, ingestible diagnostic devices, and perhaps even decorative electronic tattoos. A single-shot reformulation of zanamivir (originally the inhaled flu drug Relenza) provided 76.1% flu protection in a 5,000-participant trial—far exceeding the roughly 40-45% offered by annual flu vaccines. Because zanamivir targets neuraminidase in a way that inactivates it if the virus tries to mutate around the drug, trapping newly-made viral copies inside their host cells, this approach works across all flu strains and could bypass the annual guessing game of trivalent vaccine formulation.

In this special live episode recorded from the SLEEP 2026 annual meeting in Baltimore, host Dr. Seema Khosla welcomes Dr. Sanjay Patel, director of the clinical sleep program at University of Pittsburgh Medical Center, to discuss groundbreaking medications for sleep disorders poised for FDA approval in 2026 and 2027. The pharmaceutical landscape for sleep medicine is undergoing unprecedented transformation. Dr. Patel surveys the emerging drug pipeline that will fundamentally change how clinicians treat obstructive sleep apnea, narcolepsy, and idiopathic hypersomnia. For obstructive sleep apnea, Dr. Patel discusses AD-109 (atomoxetine and R-oxybutynin), explaining the mechanistic rationale and practical considerations including use with tirzepatide. The Incannex drug combining dronabinol and acetazolamide receives analysis for different patient populations, and sultiame is discussed as a carbonic anhydrase inhibitor option. A critical framework emerges: Should treatment be symptom-based or airway-focused when PAP-intolerant patients present? Tirzepatide, the GLP-1 agonist FDA-approved for moderate-to-severe OSA, receives comprehensive coverage including muscle loss concerns, long-term use, and emerging oral GLP-1 options. Retatrutide, the triple-hormone agent combining GLP-1, GIP, and glucagon, is also discussed. The episode's most exciting segment focuses on orexin agonists for narcolepsy. Three pharmaceutical companies—Alkemeres, Centessa (purchased by Lilly), and Takeda—are developing these mechanistically novel agents. Dr. Patel clarifies how these medications differ, discusses why one medication disrupted nocturnal sleep (suggesting continued roles for oxybates), and addresses how clinicians will choose between similar medications. Dr. Patel emphasizes a fundamental question: Should the field prioritize symptom management versus airway patency for OSA, and mechanistic approaches versus symptom management for narcolepsy? Whether you're interested in emerging OSA treatments, narcolepsy innovations, or the future of pharmacological sleep medicine, this live episode provides essential updates on medications that will soon reshape clinical practice. Join us for this exciting conversation about how sleep medicine will transform in the coming years.

GLP-1 receptor agonists have become some of the most talked-about medications in recent years. You may have heard names such as liraglutide, semaglutide (Ozempic and Wegovy), and tirzepatide (Mounjaro). These treatments have attracted attention because they can significantly reduce appetite and support weight loss while also helping to manage blood glucose levels. The breakthrough came when researchers developed long-acting versions of hormones naturally released by the body after eating, including GLP-1 and, in some cases, GIP. These hormones help regulate hunger and promote feelings of fullness. While the body's natural response lasts only a short time, modern medications extend these effects for up to a week with a single injection. Since results from major clinical trials emerged in the early 2020s, GLP-1 therapies have transformed obesity treatment, delivering weight-loss outcomes that surpass those achieved by previous medications and offering new hope for people struggling with weight management. - Laureate Professor Clare Collins, internationally distinguished leader in nutrition and dietetics, University of NewcastleSee omnystudio.com/listener for privacy information.

It's In the News - a look at the top diabetes headlines and stories happening now. Our top stories: More information about type 1 and COVID, including the vaccine, why is the latest GLP-1 medication, not yet FDA approved, showing up all over the place, what table sugar and vinegar could mean for drug costs, a new inhaled insulin study and much more  I'll see you at Friends for Life next week. Come find me at Table T18 Learn more about our in-person events here: https://diabetes-connections.com/events/ Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Transcript & links:    Okay.. our top story this week: XX A large Swedish study found that the increased risk of being diagnosed with type 1 diabetes after COVID-19 infection is mostly limited to the first 30 days after infection and does not continue long term. Researchers followed nearly the entire Swedish population under age 80 from 2020 through 2023 and found that while SARS-CoV-2 infection was linked to a temporary rise in new type 1 diabetes diagnoses, the risk declined over time. The study also found no evidence that COVID-19 vaccination increases the long-term risk of developing type 1 diabetes. Vaccination did not significantly change the relationship between COVID-19 infection and diabetes risk, and any small increase in diagnoses seen among adults shortly after a first vaccine dose was not seen after later doses or during longer follow-up. The researchers concluded that their findings do not support changing current COVID-19 vaccination recommendations because of concerns about type 1 diabetes risk. https://www.infectiousdiseaseadvisor.com/news/covid19-infection-may-increase-short-term-type-1-diabetes-risk/ XX Two new studies are challenging the traditional view that type 1 diabetes develops solely because the immune system attacks insulin-producing beta cells. Researchers from Indiana University found evidence that beta cells themselves may play an active role in determining whether they survive or succumb to the stresses that lead to type 1 diabetes. In the first study, scientists discovered that some healthy human beta cells can quickly activate an antiviral defense system when exposed to interferon-alpha, an immune signal often produced during viral infections. This response relies on molecules called reactive oxygen species (ROS), which are usually associated with cell damage but, in this case, appeared to help switch on protective antiviral genes. Researchers found this defense program in healthy cells and in people at risk for type 1 diabetes, but not in beta cells from people who already had the disease. The findings suggest that losing this built-in defense mechanism may make beta cells more vulnerable during the development of type 1 diabetes. The second study focused on autophagy, the process cells use to recycle damaged or worn-out components. Using a new imaging technique, researchers observed that beta cells in a mouse model of type 1 diabetes showed defects in autophagy before blood sugar levels began to rise and even before a full immune attack was underway. This suggests that problems inside the beta cells may occur early in the disease process rather than being caused entirely by the immune system. Together, the studies point to a more complex picture of type 1 diabetes. While they do not show that beta-cell defects cause the disease, they suggest that differences in how beta cells respond to stress, viral signals, and cellular damage may influence who develops type 1 diabetes and how the disease progresses. https://medicalxpress.com/news/2026-06-beta-cells-players-diabetes.html XX Researchers have created the most detailed map yet of how the human pancreas develops during childhood, offering new clues about why children are especially vulnerable to developing diabetes. The study, published in Nature Communications, examined pancreatic tissue from 123 children without diabetes, ranging from newborns through age 10. Using advanced imaging techniques, scientists tracked how insulin-producing islet cells grow and mature during the first decade of life. The researchers found that pancreas size varies dramatically at birth, with some infants having pancreases nearly four times larger than others. They also discovered that insulin-producing beta cells grow more slowly after birth than previously thought, suggesting that much of a person's lifelong beta cell capacity may be established before birth and during early childhood. Other findings showed that insulin-producing cells mature earlier than glucagon-producing cells and that new hormone-producing cells may continue to form after birth. The researchers hope this new understanding of pancreas development will help scientists identify diabetes risk earlier and develop better strategies for prevention and treatment in children. https://news.vumc.org/2026/06/29/unlocking-diabetes-secrets-pediatric-organ-donors-help-map-a-path-to-a-cure-and-prevention/   XX At the American Diabetes Association annual meeting, 2-year results from the SUPPRESS-EARLY trial showed that initiating tirzepatide (Mounjaro, Zepbound) early in the course of type 2 diabetes led to substantially higher rates of near-normal glycemic control and also led to broader metabolic improvements compared with intensive conventional therapy.   In this MedPage Today video, investigator Stefano Del Prato, MD, of the University of Pisa in Italy, discusses the findings.     Following is a transcript of his remarks:   What happened is that in the tirzepatide-treated arm, 85% of the population at the end of the second year was on the maximum dose of tirzepatide 15 mg. And then the remaining 15 with the different doses.   Interestingly, in the population that had been treated with the intensive conventional approach, 85% of them ended up to have, on top of metformin, a GLP-1 receptor agonist, mainly represented by subcutaneous semaglutide [Ozempic, Wegovy], 60+%, another 15% on oral semaglutide [Rybelsus], and the remaining on dulaglutide [Trulicity].   And I have to say that maybe the recommendation to really push along the line to try to achieve and to strive to achieve [glycemic] control was successful in these individuals. Because the population that had been recruited in the study started off with a baseline A1C of 7.8% and it went down to 6.3% in the conventionally intensive treatment, which is not bad at all, on average is below the target of 6.5%.     However, when we look at the effect of tirzepatide, the final level of A1C at the end of the second year was 5.6%, which is on average below the upper limit of the normal range for A1C, 5.7%. This also translates into more people not only achieving normal glycemia, if we can define normal glycemia as A1C below 5.7%, greater than what we observed in conventionally treated individuals. So it was around three times more people achieving an A1C of 5.7%, in the range of around 65%, as compared to 28% with people on a conventional optimized treatment.   Now, this is not surprising knowing the potency of tirzepatide. But again, going back to the rationale of the design, can we change what is the natural history of the disease? This seems to be at least of interest and it's possibly changing the trajectory of the disease for glycemic control, as I mentioned, but also in terms of the body weight and waist circumference because both body weight and waist circumference went much lower with tirzepatide compared to the conventional treatment.   Tirzepatide also was associated with an improvement in the lipid profile, in particular with the LDL, triglycerides, and the triglyceride concentration and non-HDL cholesterol, and also with a statistically significantly lower systolic blood pressure with a numerical reduction in the diastolic blood pressure.   And also the other thing that probably will ... become more apparent with the study continuing is that the investigators were allowed to add on any other treatment ... needed to achieve their target. So tirzepatide was just metformin and tirzepatide. In the control group, there was already 10% of people who were receiving two drugs on top of the metformin.   So another potential result of the trial is that it's possible to achieve and maintain better glycemic or better metabolic control over the time without really needing to increase the number of medications in order to achieve that goal. And we know that type 2 diabetes is a progressive condition often requiring intensification of the treatment.   So these initial results really stand for a great opportunity with tirzepatide. Of course, we need to wait for the 4 years just to confirm that this is indeed the case, but the initial result seems to point along that line. https://www.medpagetoday.com/meetingcoverage/adavideopearls/121967 XX A study from the University of Virginia found that high blood pressure is extremely common among people with diabetes, even among those who believe their blood pressure is under control. Researchers measured blood pressure in 172 adults with type 1 or type 2 diabetes during routine eye clinic visits and found that only 8% had normal readings. About half had stage 2 hypertension, and more than 10% had blood pressure levels high enough to be considered a medical emergency. The study also revealed that many patients were unaware of how serious their blood pressure problems were. Among those who thought their hypertension was well controlled, more than half still had stage 2 hypertension. Nearly 60% of participants were advised to contact their primary care provider, and one patient required an emergency department referral. Most patients supported blood pressure screening during eye exams, leading researchers to suggest that routine blood pressure checks in ophthalmology clinics could help identify undiagnosed or poorly controlled hypertension before it leads to serious complications such as heart attack, stroke, or worsening diabetic eye disease. https://medicalxpress.com/news/2026-06-routine-eye-exams-reveal-stage.html XX What is going on with retatrutide? This is the next generation GLP-1 but it's not authorized outside of clinical trials. Big investigation by CBS shows retatrutide is for sale all over the internet, a phenomenon they say has no modern precedent. CBS News identified more than 120 websites selling or promoting retatrutide, including more than 50 clinics staffed by licensed medical professionals. After being contacted by CBS News, at least 21 clinics abruptly removed retatrutide from their websites or changed the language to state they don't offer it. Others defended prescribing it, saying they're confident enough in results from clinical trials sponsored by drugmaker Eli Lilly that they didn't need to wait for the FDA's independent, rigorous review. An FDA spokesperson said retatrutide "has not been found safe or effective for any condition," adding that it "cannot be manufactured or distributed except for investigational use." The Justice Department is prosecuting two cases – in Utah and Florida – involving the sale and prescription of retatrutide. But the first line of enforcement is often at the state level. Ohio's Board of Pharmacy has taken action against several pharmacies and clinics providing retatrutide, and just last month, Alabama's Medical Board warned physicians against prescribing research-grade medications. The FDA has sent 14 warning letters to companies that have advertised retatrutide since 2024. Of these, at least six have continued to offer it online, including a business called Pink Pony Peptides. A TikTok account associated with the firm responded to the warning in April by taunting the FDA, boasting that the business "just had the best 24 hours ever." In May, Eli Lilly announced that participants in a large clinical trial taking the highest dose of retatrutide lost an average of 28% of their body weight over 80 weeks. Side effects – including nausea, diarrhea, constipation and vomiting – were comparable to similar therapies, the company said. "Anyone purporting to sell retatrutide to consumers is breaking the law," an Eli Lilly spokesperson said https://www.cbsnews.com/projects/2026/experimental-weight-loss-drug/ XX Pioneering research has developed a new way of creating carbohydrate-based medicines, which could ultimately replace costly drugs for common health conditions, using two cheap basic ingredients – table sugar and vinegar. These medications include SGLT2 inhibitors, widely prescribed drugs used to treat type 2 diabetes, heart failure and chronic kidney disease. Co-lead author Professor Phil Baran, Dr. Richard A. Lerner Endowed Chair at Scripps Research, in San Diego, California, said: "The point of this is to show that anyone in a garage can make an SGLT2 inhibitor with reagents that are widely available. We have not patented this method, so we welcome any generic drug company – or anyone else – who wants to use it to help bring costs down for patients." https://www.newswise.com/articles/new-study-shows-table-sugar-could-hold-a-cheaper-quicker-key-to-making-vital-drugs-for-diabetes-heart-failure-and-chronic-kidney-disease XX England and Wales approve teplizumab to slow progression of T1D. At the moment, the Scottish Medicines Consortium does not have an appraisal of Tzield on the go, so, there is likely to be a disparity in access within the UK for the time being. In Northern Ireland, access will depend on a review and adoption of NICE guidance.  Sanofi is expecting to see an uptick in momentum thanks to two subsequent FDA approvals, one in children as young as one with stage 2 T1D, and a second to delay the decline in endogenous insulin production in children aged eight to 17 years recently diagnosed with stage 3 T1D. btw you might here more people referring to stage 4 diabetes. They've added that to include people diagnosed with type 1 who've been on insulin for a longer period of time – basically long enough to not be eligible for the current guidelines for Tzield. https://www.bbc.com/news/articles/ce8mzd94r76oXX XX Obesity Association, a division of the American Diabetes Association® (the association), announced the next section in the Standards of Care in Overweight and Obesity, "Screening, Diagnosis, Evaluation, and Staging of Obesity in Adults," published in Diabetes, Obesity, and CardioMetabolic CARE® and BMJ Open Diabetes Research & Care.  Key highlights of the guidance: Early screening: Annual BMI screening with emphasis on tracking weight trends to identify risk earlier, including a longitudinal life-event weight graph tool for standardized assessment. Enhanced diagnosis: Combines BMI with waist measurements and population-specific thresholds to improve accuracy. Notably, the guidelines recommend that BMI in the overweight range together with central adiposity measurements warrant a formal obesity diagnosis. Comprehensive evaluation: Holistic assessment including medical, behavioral, and social factors. Offers a fully integrated obesity diagnostic algorithm. Risk stratification: Use of tools like the Edmonton Obesity Staging System to guide care. Chronic care approach: Ongoing monitoring and follow-up to support long-term management. Reducing bias: Promotes person-centered, non-stigmatizing care and system-level improvements at the clinical workflow level and encourages screening for prior weight bias/stigma experiences. https://www.prnewswire.com/news-releases/new-standards-of-care-in-overweight-and-obesity-section-screening-diagnosis-evaluation-and-staging-of-obesity-in-adults-302809670.html XX Dexcom (Nadsaq:DXCM) today announced the launch of its fully reimagined Stelo over-the-counter (OTC) sensor app experience. San Diego-based Dexcom plans to formally begin the new app rollout in July for Apple iPhone and Android users in the U.S. Dexcom said its reimagined app aims to make glucose insights easier to understand and act on. It hopes to help build awareness of how food, activity, sleep and stress influence overall wellbeing.   The company also reiterated plans to launch Stelo internationally. It expects to bring the sensor to the UK, Australia, New Zealand and South Korea later this year, continuing into 2027. https://www.drugdeliverybusiness.com/dexcom-launches-enhanced-stelo-app/ XX MannKind Corporation recently announced it received a grant from Breakthrough T1D to support the INHALE-1 clinical study of Afrezza, its ultra rapid-acting inhaled insulin, in newly diagnosed pediatric type 1 diabetes patients aged 10 to under 18 years. This external funding for a trial focused on early use of Afrezza in children highlights growing third-party support for inhaled insulin in pediatric diabetes care. https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mnkd/mannkind/news/afrezza-pediatric-trial-grant-might-change-the-case-for-inve XX Alexander Zverev heads into Wimbledon with plenty of momentum. The French Open champion returns to the All England Club looking to build on his first Grand Slam title and gain ground on Carlos Alcaraz in the race for the No. 2 spot in the ATP rankings. Zverev has an opportunity to make up points quickly after a first-round exit at Wimbledon last year. But his final tune-up before Wimbledon came with an unexpected challenge. During his semifinal loss to Taylor Fritz at the Halle Open, Zverev said a malfunctioning glucose sensor led to serious diabetes management issues on court. The sensor incorrectly showed his blood sugar was high when it was actually low, causing him to take more insulin than needed. "I had huge problems with the sugar because the sensor I use gave me a completely incorrect reading," Zverev said after the match. "During the match, or rather during the first 45 minutes, I had to consume about 350 grams of sugar. I felt absolutely terrible." Despite feeling unwell, Zverev pushed the match to three sets before falling 6-7(4), 6-4, 7-5 to Fritz. He credited his opponent with playing the better match and said the diabetes-related issue was not an excuse for the result. Zverev, who was diagnosed with type 1 diabetes at age 4, uses Medtronic diabetes technology to help manage his glucose levels while competing on the ATP Tour. He said the sensor error was the first major problem he has experienced after nearly a decade of using the technology. The German said the incident should not affect his Wimbledon preparations. With the sensor issue behind him, Zverev will begin his Wimbledon campaign focused on adding another strong result to what has already been a breakthrough season.   https://www.reuters.com/sports/tennis/zverev-says-glucose-sensor-malfunction-affected-halle-semi-final-loss-fritz-2026-06-21/

Check Out BioVitalis Peptides: https://biovitalis.org/ (Use Promo Code: GSD10 for 10% off)   Check Out Jim Brown's Substack Blog: https://substack.com/@forj   *Disclaimer: This NOT medical advice. Please make sure to seek your own medical professional for medical advice.

0:00- Intro1:00- Tirzepatide 5:00- Using tirzepatide vs strict discipline14:00- Accurately tracking calories23:45- Differences in metabolism vs appetite 30:00- Potential consequences of being very lean34:00- Incorporating refeeds 35:00- Being shredded42:00- Using medications48:30- Why not retatrutide?51:15- How is strength while this lean?55:00- Realities of later natural lifting1:03:45- Kinoclinic Website and Coaching: https://brainsandgainspodcast.com/Instagram: https://www.instagram.com/dave_maconi/David Protein Link: https://davidprotein.com/BAGCode: BAGhttps://www.youtube.com/channel/UCW-PI9YMJ6SXPiqXy2FYfLg/join-For those looking to support the channel and our donations to various charities, please consider the above link to become a member and have the opportunity to appear on the channel!

In this podcast, Jennifer Green, MD, and Jay H. Shubrook, DO, FAAFP, FACOFP, share strategies for integrating incretin-based therapies in type 2 diabetes (T2D) management in the primary care setting, including: Importance of moving beyond a glucose-centric approach to T2D care  Current evidence for incretin-based therapies in T2D Rationale for integrating these therapies into the primary care setting Shared decision-making strategies to discuss optimal T2D treatment options with patients Timing for endocrinology referral Presenters: Jennifer Green, MD Professor of Medicine Division of Endocrinology Duke Clinical Research Institute Duke University School of Medicine Durham, North Carolina Jay H. Shubrook, DO, FAAFP, FACOFP Professor, Diabetologist Department of Clinical Sciences and Community Medicine Touro University California, College of Osteopathic Medicine Vallejo, California Full program link: https://bit.ly/4uSKCqv Get access to all of our new podcasts by subscribing to the Decera Clinical Education Multispecialty Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

A few years ago, I came across a quote that said:"I think the key to a happy life as an adult woman is to channel your inner weird little girl and make her happy."It immediately resonated with me.I was the kid making potions in the yard, obsessed with magic books, fortune tellers, mood rings, crystals, and all things mystical. And the older I get, the more I realize those parts of me never disappeared—they just got buried under adulthood and responsibility.In this episode, I'm talking about whimsy—not as a trend, but as a way of reconnecting with yourself. I'm sharing what's on my whimsical summer list, why I've been intentionally making more room for wonder, and how this connects to one of the core principles of Irresistible You: Feed Your Soul.Because maybe creating a magical life isn't about becoming someone new.Maybe it's about remembering who you've been all along. ✨

Semaglutide. Tirzepatide. Retatrutide. The peptide conversation has taken over every gym, group chat, and social media feed. But the part about muscle loss, osteopenia, and what the gray market is actually selling you? That part is getting buried. Chalene Johnson sits down with Adam Schafer, co-host of Mind Pump, one of the top fitness podcasts in the world with nearly half a billion downloads. Adam spent three and a half years running real test groups on GLP-1s including Ozempic and Wegovy. What he found changed his perspective entirely and he is not holding back. This conversation covers what is actually driving muscle and bone density loss in women over 40 and 50, why the scale and the mirror are lying about body composition, and what most women are getting wrong about building real strength in midlife. Plus the truth about the gray market and what those peptides may actually contain. This is the conversation the fitness industry is not having and it is one every woman over 40 needs to hear.

In part two of the GLP-1 series, Melissa gets practical. What does it actually feel like to be on this medication? What does responsible use look like day to day? And how do you get the best results at the lowest effective dose possible?Whether you just started, you're a few months in, or you're wondering why you're not seeing the results you expected — this episode is for you.IN THIS EPISODE, YOU'LL LEARN:Why you forget about food on a GLP-1 and why that feeling of relief is also where your responsibility beginsWhat the flat affect actually is, why it happens, and what it tells you about your doseWhy GLP-1 receptors live in the brain's reward center — and what that means for your dopamine, your drive, and your nervous systemThe difference between microdosing and the lowest effective dose (and why that distinction matters more than the label)FDA-approved dosing for semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) — and where Melissa would actually startWhy digestion has to come first before or while on this medicationThe truth about blood sugar stability on a GLP-1 and why the medication doesn't do that work for youWhy women on GLP-1 are losing muscle without realizing it — and exactly what to do about itProgressive overload: what it actually means and why going through the motions isn't enoughWhy Melissa recommends Cronometer over MyFitnessPal for tracking on a GLP-1Hair loss — medication side effect or weight loss side effect? Melissa breaks down the differenceFatigue — why it's actually both, and what to do depending on which one it isWhy perimenopause symptoms can get louder on a GLP-1 and what's happening hormonallyHow to know if you're actually at a plateau (hint: four weeks is the threshold)What to do when you're at max dose and the scale still isn't movingHow long is it okay to stay on a GLP-1 — and what the long-term concerns actually areTIMESTAMPS:00:00 — Welcome back + recap of episode one 01:45 — What it actually feels like when you first start 03:30 — The flat affect and the dopamine loop 07:50 — Strength training as a natural dopamine regulator 10:00 — The lowest effective dose and what microdosing actually means 12:00 — Semaglutide dosing overview (Wegovy, Ozempic) 13:45 — Tirzepatide dosing overview (Zepbound, Mounjaro) 15:00 — How to advocate for a lower starting dose with your provider 16:00 — Melissa's personal experience: 1 mg tirzepatide for inflammation 23:30 — Making the medication work hard for you: the foundation 25:00 — Digestion first — why gut health matters before you start 26:30 — Blood sugar stability is your responsibility 29:00 — Protein first, always 31:00 — Why women on GLP-1 are losing muscle 33:30 — Progressive overload — what it actually looks like 35:00 — Track your food — why Cronometer and why it's non-negotiable 38:30 — Side effects: medication vs. weight loss (two different categories) 39:00 — Hair loss explained 40:50 — Fatigue explained 42:00 — Nausea, constipation, gut symptoms 42:45 — Perimenopause, hormonal shifts, estrogen dominance44:30 — How to know if you're actually at a plateau 48:00 — Max dose: what to do when you're there 48:30 — How long is it okay to stay on a GLP-51:00 — Download the GLP-1 Support Guide + closeRESOURCES:Download the GLP-1 Support Guide — everything you need to use this medication responsibly: workouts with logging space, protein meal plan, nutrition framework, and tracking tools. melissaeichwellness.com/GLP1guideBook a free consultation with Melissa — whether you're considering GLP-1, already on it, or wanting gut or hormone support while on it: https://melissaeichcoaching.practicebetter.io/#/6490bd200e37c64b346b25c8/bookings?s=6a0cb936104f4243883a46dfGut Healing Program or Complete Hormone Program: https://melissaeichcoaching.practicebetter.io/#/6490bd200e37c64b346b25c8/bookings?s=69fe864f4b36932a1ec4aba4Related episodes:Episode [#179]: GLP-1 Series, Part 1 — The Shame, the Gray Area, and Weight Loss Resistance: https://podcasts.apple.com/us/podcast/179-glp-1-for-midlife-women-where-to-begin-part-1-3/id1650475536?i=1000771142749DUTCH test series — perimenopause, weight loss resistance, and estrogen detox - https://podcasts.apple.com/us/podcast/176-perimenopause-weight-gain-and-the-dutch-test/id1650475536?i=1000767363294CONNECT WITH MELISSA:Instagram: @melissa_eich Website: melissaeichwellness.com Email: melissa@melissaeichwellness.comABOUT THE SHOW:Body-Led by Design is a podcast for women who are done guessing and ready to understand what's actually happening in their bodies. Hosted by Melissa Eich, registered nurse, hormone and nervous system coach, and somatic practitioner, each episode brings the real conversations from her practice so you can walk away more informed, more empowered, and a little less alone in what you're navigating.LEAVE A REVIEW:If this episode resonated with you, a five-star review means the world. It helps more women find this podcast and get the information they actually need.SEO KEYWORDS:GLP-1 side effects, semaglutide weight loss, tirzepatide lowest effective dose, microdosing GLP-1, hair loss on Ozempic, muscle loss GLP-1, weight loss plateau GLP-1, GLP-1 fatigue, Wegovy responsible use, perimenopause GLP-1, how long to stay on GLP-1, GLP-1 support women over 40

Calum Raistrick, Niall Darwin (onepunchnaz)APR Health Solutions Peptides: www.aprhealthsolutions.com - code nyleOptimize HRT Clinic: https://members.optimize-hp.com - code nyleMerch: https://www.aykons.com/nylePlease share this episode if you liked it. To support the podcast, the best cost-free way is to subscribe and please rate the podcast 5* wherever you find your podcasts. Thanks for watching.To be part of any Q&A, follow trensparentpodcast or nylenayga on instagram and watch for Q&A prompts on the story  https://www.instagram.com/trensparentpodcast/Huge Supplements (Protein, Pre, Defend Cycle Support, Utilize GDA, Vital, Astragalus, Citrus Bergamot): https://www.hugesupplements.com/discount/NYLESupport code 'nyle' 10% off - proceeds go towards upgrading content productionYoungLA Clothes: https://www.youngla.com/discount/nyleCode ‘nyle' to support the podcastLet's chat about the Podcast:Instagram: https://www.instagram.com/trensparentpodcast/TikTok: https://www.tiktok.com/@transparentpodcastPersonalized Bodybuilding Program:  https://www.nylenaygafitness.comRP Hypertrophy Training App: rpstrength.com/nyle (code nyle)0:00:00 - Intro0:02:04 - University Days & Naive PED Use0:05:03 - Gut Health & The 1.5g Protein Limit0:10:05 - Midsection Vacuum & Classic Weight Caps0:16:24 - The Real Cause of Waist Growth0:19:34 - Total Drug Load vs. Visceral Fat0:22:30 - Conditioning Secrets: Classic vs. Open0:28:28 - Niall's 12-Week Pittsburgh Prep Plan0:32:47 - Compound Tapering & Injection Risks0:35:02 - Extreme Prep Protocols: Martin & Boss0:40:57 - Systemic Stress & "Landing the Plane"0:43:12 - Blowing a Load the Night Before Show0:43:34 - John Meadows' "Grainy Skin" Secrets0:45:45 - Linear Peaking vs. Volatile Refeed Gauging0:48:45 - Strategic Atrophy & Leg Volume Slashes0:50:15 - Quad & Glute Volume Tiers0:52:08 - Tyler Smith's Extreme Leg Volume Slash0:53:19 - Peptide Protocols & Organ Protection0:55:21 - The Elite Client Portfolio0:57:11 - Coaching Content Creator Brandon Harding1:00:03 - Influencer Stress & Off-Season Fat Fear1:01:37 - Off-Season Fat Anxiety1:02:06 - What Makes a Coach Most Anxious?1:04:16 - Bodybuilding Page Tags & Lineups1:05:00 - Analyzing Kyron Holden & Ryan Terry1:06:47 - Managing Cortisol, Stimulants & Sleep1:11:46 - Advanced Peptides: SLU-332 & GC-11:12:44 - T3 Abuse vs. T4 & Sobetirome Replacement1:13:33 - GLP-1 Downsides in Contest Prep1:14:25 - Tirzepatide for Post-Show Reverse Phases1:16:05 - Why GLP-1s Ruin Peak Week1:20:36 - Compounding vs. Research Chemicals1:21:21 - Blood Panels & Wellness Specialists1:23:16 - GH & Insulin in Classic Physique1:24:46 - Insulin Dosing as an Off-Season Support1:25:24 - Nighttime GH Bolus vs. Microdosing1:27:00 - Patrick Tuor's Insulin-GH Synergy Theories1:28:55 - Lantus vs. Rapid-Acting Insulin Placement1:30:40 - Working with Niall Darwen1:31:29 - Height Measurements and Weight Caps1:32:44 - Height Manipulation & Spinal Decompression1:35:03 - Niall's Future Back Density Strategy1:36:26 - Pittsburgh Pro Post-Weigh-In Load1:37:37 - Off-Season Fiber & Gut Linings1:39:19 - Oral Steroid Toxicity & Digestion Dampening1:40:41 - Low-Dose Oral Strategies1:42:06 - 100mg Winstrol Motility Shutdown1:46:09 - Post-Show Recovery Phase vs. Rebound1:48:09 - Systemic Muscle Memory & Cell Sensitivity1:49:05 - Scientific Training Philosophy1:50:53 - Zachariah's 34kg Hypertrophy Miracle1:52:24 - Slow Eccentrics & Mind-Muscle Intent1:54:40 - Hyper-Focus During Sets1:56:53 - Comprehensive Blood Work Markers1:57:58 - Cruising Protocol Adjustments2:00:15 - Dietary Fats with Pre-Workout Insulin2:01:32 - Coaching Dynamics of Close Friends2:05:00 - Eric's Open Division Transition2:06:10 - Regional Coaching: UK Intensity vs. US Volume2:06:36 - Laszlo Karoly's Density & US Shows Strategy2:07:29 - Slow-Twitch vs. Fast-Twitch Muscle Genetics2:12:01 - Building Exceptional Muscle Mass2:14:20 - One Final Message: Back Yourself First

In this episode, I'm talking honestly about weight loss burnout. The mental exhaustion that comes from constantly thinking about food, planning meals, trying to “be good,” starting over, tracking, and feeling like your body is always a project that needs fixing.I also share what this experience has been like for me while being on Tirzepatide. The food noise is quieter, but now I find myself in this strange in-between space where I'm hungry, but nothing sounds good. I take a few bites and feel full… while somehow still feeling hungry at the same time. And honestly? I'm tired.This episode isn't anti-weight loss. It's about what happens when your entire life starts revolving around shrinking yourself, and the realization that maybe peace matters too.Because you deserve a life bigger than calorie counting.Show Notes

Hi, it's Heather and I'm so glad you're here! Welcome to the newly renamed Health, Harmony and Heather podcast! This space is dedicated to exploring social phenomena, the human condition, and how we can better connect with ourselves, each other, and the planet. In this episode, I'm thrilled to welcome back my personal clinician and friend, Lauren Rosenberg. Lauren is a highly experienced physician associate, internal medicine expert, and the founder of Vent Health, a practice dedicated to shifting the medical focus from disease treatment to true preventative care and health optimization. Today, we are stripping away the stigma and diving deep into the raw science, truth, and real solutions for perimenopause, menopause, and post-menopause. The days of women suffering in silence are over. The "One Day" Truth: Why menopause is actually just one single day in your life, and what it means for your timeline. The Hormone Rollercoaster: A breakdown of how estrogen, progesterone, and testosterone behave during your cycle—and what happens when they plummet. Symptoms Beyond Hot Flashes: From brain fog, joint pain, and "frozen shoulder" to anxiety, weight gain, and urinary changes. The WHI Study Debunked: The real story behind the 2002 Women's Health Initiative study that scared a generation away from life-saving hormone replacement therapy (HRT). The Power of Peptides: How cutting-edge tools like GLP-1s, Tirzepatide, Retatrutide, and cellular repair peptides can be paired with HRT for total vitality. At-Home Longevity Habits: The non-negotiable lifestyle habits—including grip strength, Zone 2 training, lifting weights, protein intake, and specific magnesium variations—to help you thrive. Connect with Lauren Rosenberg: Learn more at myventhealth.com or follow her on Instagram @MyVentHealth. Virtual Menopause Care: Check out Midi Health (joinmidi.com) for accessible, insurance-based virtual menopause care. Trusted Supplement Brands: Designs for Health, Pure Encapsulations, Thorne, and Metagenics. AirDoctor.  Head to www.AirDoctorPro.com  and use promo code HEATHER to get $250 off select AirDoctor air purifiers, including the 3500, 4000, and 5500 models. Plus, you'll receive a free 3 year warranty, an $84 value, and AirDoctor's 30-day money back guarantee. This is an exclusive podcast only offer, available now! Don't forget to LIKE this video, SUBSCRIBE to the channel, and hit the notification bell so you never miss an episode. Let's live the last third of our lives with vitality, strength, and harmony! #Menopause #Perimenopause #HormoneReplacementTherapy #HealthyAging #Peptides #Longevity #WomensHealth #HealthHarmonyAndHeather Learn more about your ad choices. Visit megaphone.fm/adchoices